Detail about pneumonia

Reading File

Finding Sources

Searching PubMed

"pneumonia" AND "management"

Searching the Web

pneumonia overview etiology pathophysiology treatment 2025

Reading File

Loading Image

I now have comprehensive content from multiple authoritative textbooks. Here is the detailed, well-organized answer:

Pneumonia - A Comprehensive Overview

Definition

Pneumonia is an infection of the lung parenchyma leading to consolidation of the normally air-filled alveoli. It is not a single disease but an umbrella term for a group of syndromes caused by a variety of organisms, resulting in varied manifestations and outcomes. The alveolar air spaces fill with exudate, inflammatory cells, and fibrin.

Textbook of Family Medicine 9e, p. 321
Medical Microbiology 9e, p. 235

Classification

Pneumonia is classified by several overlapping schemes:

By Clinical Setting

Type	Definition
Community-Acquired Pneumonia (CAP)	Develops in the outpatient setting or within 48 hours of hospital admission
Hospital-Acquired (Nosocomial) Pneumonia (HAP)	Develops >48 hours after hospital admission
Ventilator-Associated Pneumonia (VAP)	Occurs in mechanically ventilated patients
Aspiration Pneumonia	From aspiration of oropharyngeal or gastric contents
Pneumonia in Immunocompromised Host	Opportunistic organisms; distinct management

By Pathogen Type

Typical bacterial (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus)
Atypical (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila)
Viral (influenza A/B, RSV, SARS-CoV-2, CMV)
Fungal (Pneumocystis jirovecii, Cryptococcus, Coccidioides)

By Anatomic Pattern

Lobar pneumonia - consolidation of an entire lobe (classic in pneumococcal)
Bronchopneumonia - patchy infiltrates around bronchi (common in children, elderly)
Interstitial pneumonia - involvement of alveolar walls/interstitium (typical of viral and atypical organisms)

Epidemiology

Pneumonia/influenza is the primary diagnosis in over 1 million hospital admissions per year in the United States
In-hospital death rate: ~3.3%
Aggregate national hospital charges exceed $35 billion per year
Globally, it remains a leading cause of death, especially in low- and middle-income countries and in children
Children, elderly, and immunocompromised individuals are especially vulnerable
Textbook of Family Medicine 9e, p. 321

Etiology & Common Pathogens

Community-Acquired Pneumonia (CAP)

Streptococcus pneumoniae - the most common cause of bacterial CAP and lobar pneumonia; declining in children due to vaccination
Haemophilus influenzae - common in COPD, elderly
Mycoplasma pneumoniae - classic "atypical" or "walking pneumonia"
Chlamydia pneumoniae, Legionella pneumophila - atypical pathogens
Respiratory viruses - influenza, RSV, SARS-CoV-2

Hospital/Nursing Home Patients

Gram-negative rods: Serratia, Pseudomonas, Klebsiella, E. coli
Anaerobes (aspiration)
Multidrug-resistant (MDR) bacteria

Immunocompromised Patients

Pneumocystis jirovecii (PCP) - especially in HIV/AIDS
Cryptococcus, Coccidioides immitis
Atypical mycobacteria, CMV, fungi

Special Populations

Alcoholics: H. influenzae, aspirated anaerobes (Peptostreptococcus, Bacteroides)
Neonates: Group B Streptococcus, gram-negatives, Chlamydia trachomatis (6-8 weeks)
Children: Viral pathogens predominate; S. pneumoniae most common bacterial cause; S. aureus causes aggressive pneumonia post-varicella/measles

Pathophysiology

Entry & Early Infection

Pathogens reach the lung via:

Microaspiration of oropharyngeal secretions (most common)
Inhalation of aerosolized particles
Hematogenous seeding (rare)

Pneumococcal Pneumonia - Prototype

After aspiration, bacteria multiply rapidly in nutrient-rich alveolar edema fluid. Erythrocytes leaking from congested capillaries accumulate in the alveoli, followed by neutrophils, then alveolar macrophages. Resolution occurs when specific anti-capsular antibodies develop, facilitating phagocytosis and microbial killing. The disease typically localizes in the lower lobes (lobar pneumonia).

Hypoxemia Mechanism

Hypoxemia in pneumonia results from increased perfusion to:

Shunt units (consolidated alveoli with no ventilation)
Low V/Q regions

In mild-to-moderate pneumonia (PaO2 ~74 mmHg): shunt ~7.5%, low V/Q ~4.2% In severe pneumonia requiring mechanical ventilation: shunt ~22%, low V/Q ~11% - more than twice as high, explaining severe hypoxemia. The response to supplemental oxygen depends on the degree of shunt.

Murray & Nadel's Textbook of Respiratory Medicine, p. 960

Clinical Presentation

Two Classic Patterns

1. Typical (Bacterial) Pneumonia

Abrupt onset, high fever (39-41°C) with shaking chills
Productive cough - may have blood-tinged or rust-colored sputum
Pleuritic chest pain
Physical exam: decreased breath sounds, dullness to percussion, egophony on affected side
WBC typically elevated (>15,000 x 10³/mm³) with neutrophil predominance

2. Atypical Pneumonia

Smoldering onset, low-grade fever
Fewer constitutional symptoms
Caused by Mycoplasma, Chlamydia, Legionella, or respiratory viruses
Often called "walking pneumonia"

In Children

Malaise, cough, chest pain, tachypnea (earliest clue - disproportionate to fever), intercostal retractions
Viral: less toxic appearance, low-grade fever, wheezing
Bacterial: appear acutely ill, high fever, chills, dyspnea

General Symptoms

Cough (productive or non-productive), fever, dyspnea, malaise

Diagnosis

Chest X-Ray (CXR)

Dense consolidation of left lower lobe in patient with pneumonia caused by Streptococcus pneumoniae. From Medical Microbiology 9e

Bacterial pneumonia: Lobar consolidation and alveolar infiltrates (radiographic changes lag 1-2 days behind clinical course; can be completely normal on day 1)
Viral/atypical pneumonia: Patchy or streaky bilateral interstitial patterns + hyperinflation
Parapneumonic pleural effusions may occur

Laboratory Tests

Test	Use
CBC	Leukocytosis with neutrophilia (bacterial); normal/low WBC (viral)
Sputum Gram stain & culture	Low yield but may guide therapy
Blood cultures	Especially if bacteremia suspected
Legionella urinary antigen	High sensitivity for Legionella
Cold agglutinin test	Positive in Mycoplasma pneumoniae
AFB smear/culture	When TB is suspected
Procalcitonin & CRP	Biomarkers to distinguish bacterial vs. viral
Bronchoscopy/BAL	Reserved for immunocompromised, VAP, or non-resolving cases

Severity Assessment Tools

CURB-65 Score (1 point each):

C - Confusion
U - Urea >7 mmol/L
R - Respiratory rate ≥30/min
B - Blood pressure <90 systolic or ≤60 diastolic mmHg
65 - Age ≥65 years

Score 0-1: Outpatient | Score 2: Consider hospitalization | Score 3+: Hospitalize (consider ICU if 4-5)

Pneumonia Severity Index (PSI) - a more detailed scoring system also used for triage decisions.

Treatment

General Principles

Treatment duration: minimum 5 days, and at least 48-72 hours beyond last fever/clinical instability
Severity tools (PSI, CURB-65) should guide site-of-care decisions (outpatient vs. inpatient vs. ICU)

CAP - Outpatient (Mild, Healthy Adults)

Amoxicillin OR
Doxycycline OR
Azithromycin/Clarithromycin (in areas with low macrolide resistance)

CAP - Inpatient (Non-ICU)

Beta-lactam + macrolide (e.g., amoxicillin-clavulanate + azithromycin), OR
Respiratory fluoroquinolone alone (levofloxacin, moxifloxacin)

CAP - ICU / Severe

Beta-lactam + azithromycin or beta-lactam + respiratory fluoroquinolone
Add MRSA coverage (vancomycin or linezolid) if MRSA risk factors present

HAP / VAP

Broad-spectrum coverage targeting Gram-negatives and MRSA
Agents: piperacillin-tazobactam, cefepime, or carbapenems ± vancomycin/linezolid

Atypical Organisms

Mycoplasma/Chlamydia: macrolides or doxycycline
Legionella: fluoroquinolones or azithromycin

Key Note

A meta-analysis found no advantage for antibiotics active against atypical pathogens compared to beta-lactams alone in non-severe CAP, though many guidelines still recommend atypical coverage empirically. Beta-lactam antibiotics are as effective as macrolides and quinolones in most cases.

Textbook of Family Medicine 9e, p. 322

Complications

Complication	Notes
Parapneumonic effusion	~25% of pneumococcal pneumonia; generally mild hypoxemia
Empyema	Purulent pleural effusion; rare but serious
Lung abscess	Uncommon in pneumococcal except serotype 3
Bacteremia	Increases mortality, especially in elderly/asplenic
Respiratory failure / ARDS	Severe pneumonia with extensive consolidation
Pneumatoceles	Especially with S. aureus in children
Septic shock	Multi-organ dysfunction

Splenic Dysfunction

Patients with splenic dysfunction or post-splenectomy are at high risk for fulminant pneumococcal disease because of decreased bacterial clearance from blood and defective early antibody production. Overall mortality is 5% but considerably higher with bacteremia, serotype 3, elderly patients, and asplenic individuals.

Prevention

Vaccines

Influenza vaccine: Annually for patients >50 years, those with chronic lung disease, diabetes, immune dysfunction, or other chronic organ failure
Pneumococcal vaccine (PCV/PPSV23):
- Revaccinate after 10 years if the first vaccine was given before age 65
- Universal pneumococcal vaccination in children has significantly reduced S. pneumoniae CAP

Infection Control

Hand hygiene, isolation precautions
Head-of-bed elevation at 30-45° for ventilated patients (shown to reduce VAP risk)
Oral care bundles in ICU patients

Summary Table

Feature	Typical Bacterial	Atypical	Viral
Onset	Abrupt	Gradual	Gradual
Fever	High, with chills	Low-grade	Low-grade
Cough	Productive, purulent	Dry or mild	Dry
CXR	Lobar consolidation	Interstitial/patchy	Bilateral interstitial
WBC	Elevated, neutrophilia	Normal or mildly elevated	Normal or low
Common organisms	S. pneumoniae, H. influenzae	Mycoplasma, Legionella	Influenza, RSV

Sources:

Textbook of Family Medicine 9e (Elsevier), pp. 321-323
Medical Microbiology 9e, pp. 235-236
Murray & Nadel's Textbook of Respiratory Medicine, p. 960
IDSA/ATS Clinical Practice Guidelines for CAP (2019)

Tell me detail about LRTI . I am a respiratory medicine 1st year PGT

Reading File

Finding Sources

Searching PubMed

"lower respiratory tract infection" AND "guidelines"

Searching the Web

LRTI lower respiratory tract infection classification etiology pathophysiology management guidelines 2024 2025

Reading File

Finding Sources

Reading File

Loading Image

This is a PGT-tailored, exam-ready overview. Here's a summary of what's covered:

What This Covers (PGT Summary Map)

The guide above covers all 6 major LRTI entities at the depth expected of a 1st-year respiratory medicine PGT:

Acute Bronchitis/Tracheitis - definition, viral etiology, why antibiotics are NOT indicated, stewardship
CAP - full pathogens by setting, CURB-65, ATS/IDSA severe CAP criteria (with flowchart), antibiotic algorithm (outpatient → non-ICU → ICU → MRSA/Pseudomonas), 2026 ATS update
HAP/VAP - CDC/NHSN VAE surveillance algorithm (VAC → IVAC → possible/probable VAP), organism resistance profile, 7-day antibiotic target, PK/PD dosing principles
Aspiration Pneumonia and Lung Abscess - anaerobic microbiology, virulence factors, management
Empyema - pathophysiology and management
Diagnostics/Biomarkers - sputum quality, CRP-guided prescribing (NICE), procalcitonin, NGS

Key points to remember for exams:

Acute bronchitis = no antibiotics (but 71% still get them - classic MCQ trap)
CURB-65 score ≥3 = hospitalize; ATS major criteria (1 of 2) or minor criteria (3 of 9) = ICU
HAP/VAP treatment = 7 days (not longer - more MDR with prolonged courses)
Daptomycin is inactivated by pulmonary surfactant - cannot be used for lung infections
Low procalcitonin does NOT rule out bacterial pneumonia - never withhold treatment on PCT alone

Tell me about Asthma in detail

Finding Sources

Searching PubMed

"asthma" AND "management guidelines"

Searching the Web

GINA 2025 2026 asthma guidelines update management

Reading File

Reading Web Page

https://www.pulmonologyadvisor.com/features/asthma-gina-2026…

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive, detailed content from Harrison's 2025, Murray & Nadel, Fishman's, ICS pharmacology sections, GINA 2026 web update, and a superb airway cross-section diagram. Let me now synthesize the full PGT-level answer:

Asthma - Comprehensive PGT Guide (Respiratory Medicine)

Sources: Harrison's Principles of Internal Medicine 22E (2025), Murray & Nadel's Textbook of Respiratory Medicine, Fishman's Pulmonary Diseases and Disorders, GINA 2026 Strategy Report

1. Definition

Asthma is a disease characterized by episodic airway obstruction and airway hyperresponsiveness, usually accompanied by airway inflammation. In most cases, the obstruction is reversible, but in a subset of patients a component may become irreversible. In a large proportion, airway inflammation is eosinophilic, but some patients present with differing types (neutrophilic, mixed, or paucigranulocytic).

Harrison's Principles of Internal Medicine 22E, Chapter 298

2. Epidemiology

Affects ~300 million people worldwide; one of the most common chronic lung diseases
Prevalence in adults: ~7-10% in high-income countries
Increased prevalence with urbanization, Western lifestyle, obesity
Can occur at any age; in children, more common in boys; in adults, more common in women
Asthma deaths remain significant - GINA 2026 emphasizes fatality risk indicators as a new focus

3. Pathophysiology

3.1 Structural Changes in the Asthmatic Airway

Comparison of normal vs asthmatic airway cross-section. From Harrison's Principles of Internal Medicine 22E (2025).

The diagram shows all key structural differences:

Feature	Normal Airway	Asthmatic Airway
Smooth muscle	Normal	Hypertrophy and hyperplasia
Epithelium	Intact	Denudation and shedding
Basement membrane	Thin	Collagen deposition and thickening
Lumen	Open	Invagination of mucosa due to smooth-muscle constriction
Mucus	Thin layer	Mucus hypersecretion
Vasculature	Normal	Vascular proliferation (angiogenesis)
Innervation	Normal	Neuronal proliferation
Submucosa	Normal	Cellular infiltration + airway edema

3.2 Airway Inflammation - Type 2 vs Non-Type 2

The key concept in modern asthma is understanding inflammation phenotypes:

Type 2 (T2) Inflammation (most common, ~50-70%)

Driven by: ILC2s (innate lymphoid cells type 2), Th2 lymphocytes
Key cytokines: IL-4, IL-5, IL-13 (+ alarmins TSLP, IL-25, IL-33 from epithelium)
Hallmark: Eosinophilic inflammation
Elevated FeNO (fractional exhaled nitric oxide), blood and sputum eosinophilia
Responds to: ICS, anti-IL-5 (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα (dupilumab), anti-IgE (omalizumab), anti-TSLP (tezepelumab)
Eosinophil products (ECP, major basic protein) cause airway hyperresponsiveness, mucus hypersecretion, and peribronchiolar collagen deposition

Non-Type 2 (T2-Low) Inflammation

Neutrophilic: Associated with more severe asthma, smoking, obesity, occupational exposures; often steroid-resistant
Paucigranulocytic: No obvious airway inflammation - often smooth muscle predominant
Mixed granulocytic: Both eosinophils and neutrophils - often the most severe phenotype

3.3 Mechanisms of Airway Hyperresponsiveness (AHR)

AHR is the cardinal functional feature of asthma. Causes:

Structural: Airway wall thickening (smooth muscle hypertrophy + hyperplasia + subepithelial fibrosis) → disproportionate airway narrowing
Inflammatory: Activated mast cells, eosinophils, T-cells release bronchoconstrictors (histamine, leukotrienes, prostaglandins)
Neurogenic: Stimulation of sensory nerves → reflex bronchoconstriction
Epithelial disruption: Epithelium-mesenchyme trophic unit → releases growth factors contributing to remodeling
Lymphatics: Decreased lymphatic vessel density in fatal asthma → airway edema, fibrotic changes, despite elevated VEGF-C/D

3.4 Airway Smooth Muscle (Three Roles)

Hyperresponsive to stimuli
Hypertrophy + hyperplasia → airway wall thickening
Produces chemokines/cytokines → promotes airway inflammation and mast cell survival

3.5 Subepithelial Changes (Remodeling)

Thickening of the subepithelial basement membrane from deposition of:
- Repair-type collagens, tenascin, periostin, fibronectin, osteopontin
- Primarily from myofibroblasts under the epithelium
Stiffens the airway, narrows the lumen, impairs relaxation → chronic airway obstruction

3.6 ICS Pharmacology - Key PGT Points

ICS are the mainstay of maintenance therapy
Corticosteroids reduce type 2 inflammation and airway hyperresponsiveness
Oral bioavailability comparison (critical to reduce systemic side effects):
- Beclomethasone: ~20%
- Fluticasone: ~1%
- Mometasone: <1%
- Ciclesonide: Not activated until it deposits in lung tissue (pro-drug)
Up to 80% of pMDI/DPI dose deposits in oropharynx - hence importance of low oral bioavailability
Systemic effects of ICS: short-term growth suppression in children, decreased bone mineral density, possible increased cataracts
Asthmatic airways have more proximal deposition of ICS (due to reduced airway caliber) → less systemic absorption than normal subjects

4. Classification / Phenotypes

GINA Severity Classification (Based on treatment step)

After achieving control:

Mild: Controlled on Step 1-2 (low-dose ICS or ICS/formoterol as-needed)
Moderate: Controlled on Step 3 (low-dose ICS/LABA)
Severe: Requires Step 4-5 or remains uncontrolled despite Step 4-5

Phenotypes (Clinical)

Phenotype	Features
Allergic/Atopic	Early onset, family history of atopy, elevated IgE, responds well to ICS + anti-IgE
Eosinophilic (non-allergic)	Adult-onset, high blood/sputum eosinophils, often severe, responds to anti-IL-5
Exercise-induced	Bronchoconstriction triggered by exercise; hyperventilation dries airway lining
Aspirin-exacerbated respiratory disease (AERD)	Triad: asthma + nasal polyps + aspirin/NSAID sensitivity; involves dysregulated arachidonic acid metabolism
Obesity-associated	Non-eosinophilic, difficult to control; associated with GERD, OSA
Occupational	Workplace sensitizers or irritants; improvement on vacations/weekends
Late-onset (adult)	Often severe, frequently non-atopic
Neutrophilic	Associated with smoking, infection, severe disease; steroid-resistant

5. Triggers

Category	Examples
Allergens	House dust mites, cockroach, mold, pet dander, seasonal pollens
Viral infections	Rhinovirus most common; increased AHR for 4-6 weeks post-infection; COVID-19 pandemic saw ~50% reduction in exacerbations (attributed to reduced viral infections)
Exercise + cold/dry air	Hyperventilation dries airway lining → osmolarity change → mediator release; cold air compounds this effect
Air pollution	Ozone, sulfur dioxide, nitrogen dioxide, particulate matter
Drugs	Beta-blockers (even ophthalmic drops); aspirin/NSAIDs (in AERD); ACE inhibitors (cause cough that can mimic poor asthma control)
Occupational	High MW (isocyanates, anhydrides) and low MW agents; reactive airway dysfunction syndrome (RADS) from single high-level irritant exposure
Hormonal	Perimenstrual symptoms (rapid estrogen fluctuations); pregnancy
Stress	Poorly understood mechanism
Irritants	Tobacco smoke, strong odors, cleaning products

6. Clinical Features

Symptoms (Classic Triad)

Episodic wheezing (expiratory > inspiratory)
Shortness of breath (worse on exertion, at night, or after exposure to triggers)
Chest tightness
Cough (may be the only symptom - "cough-variant asthma")
Symptoms often worse on arising in the morning or at night
History of atopy (eczema, rhinitis, food allergies) is common

Physical Examination

May be completely normal between attacks
During attacks: expiratory wheeze, prolonged expiration, use of accessory muscles, hyperinflated chest
Severe attack: silent chest (no wheeze due to minimal air entry - DANGER sign), cyanosis, pulsus paradoxus, inability to complete sentences

Asthma Control Assessment (GINA)

Domain	Controlled	Partly Controlled	Uncontrolled
Daytime symptoms	None (≤2/week)	>2/week	≥3 features of partly controlled
Night waking due to asthma	None	Any
SABA reliever use	None (≤2/week)	>2/week
Activity limitation	None	Any

7. Diagnosis

Step 1: Compatible History

Recurrent wheezing, SOB, chest tightness, or cough related to bronchoconstrictor precipitants.

⚠️ Important: More than one-third of patients with a physician diagnosis of asthma do NOT meet diagnostic criteria. Always confirm with objective testing.

Step 2: Pulmonary Function Tests

Spirometry:

FEV₁/FVC ratio <0.70 (or below LLN) confirms obstruction
Post-bronchodilator FEV₁ improvement ≥12% AND ≥200 mL = significant reversibility (confirms asthma)
Post-BD FEV₁ improvement ≥10-15% from baseline = positive

Peak Expiratory Flow Rate (PEFR):

Variability >10% (am vs pm, or day-to-day) is suggestive
Portable, inexpensive, useful for monitoring in moderate-severe asthma and pregnant women

Bronchial Provocation Testing (when spirometry normal):

Methacholine or histamine challenge
PC20 (provocative concentration causing 20% fall in FEV₁): <8 mg/mL = positive AHR
ATS impairment rating uses PC20 alongside FEV₁ and medication need

Score	PC20 (mg/mL)	Interpretation
0	>8	Normal
1	8 to >0.5	Mild AHR
2	0.5 to >0.125	Moderate AHR
3	≤0.125	Severe AHR

FeNO (Fractional Exhaled Nitric Oxide):

Marker of eosinophilic (T2) airway inflammation
≥40 ppb = elevated, suggests eosinophilic asthma, predicts ICS response
<25 ppb = ICS-responsive eosinophilic inflammation less likely

Step 3: Adjunctive Evaluation

Test	Purpose
Skin prick testing / specific IgE	Identify allergen sensitization
Blood eosinophil count	T2 phenotyping; biologic eligibility
Serum total + specific IgE	Omalizumab eligibility
FeNO	T2 inflammation marker
Sputum eosinophils	Research/difficult-to-treat asthma
CT chest	Exclude bronchiectasis, ABPA, structural causes
Chest X-ray	Baseline; exclude other diagnoses
Allergen challenge	Occupational asthma assessment

8. Comorbidities

These make asthma difficult to control and are a major focus:

Comorbidity	Key Points
Rhinosinusitis / Nasal polyps	Nasal polyps in adults + asthma → think AERD; intranasal steroids reduce AHR and ED visits; biologics increasingly used
GERD	Independent predictor of exacerbations; treatment of symptomatic GERD improves airway function; asymptomatic GERD treatment not beneficial
Obesity	2-4x more hospitalization risk; non-eosinophilic, steroid-resistant pattern; bariatric surgery improves control
OSA	Increased prevalence in asthma; apnea-hypopnea index correlates with severe exacerbations; CPAP improves QoL and reduces exacerbations; systemic corticosteroids for asthma worsen OSA by causing weight gain and pharyngeal muscle myopathy
Anxiety/Depression	Increased exacerbation rates; patients may not distinguish anxiety attacks from asthma
Vocal cord dysfunction (ILO)	Can mimic or coexist with asthma; more common in women; definitive diagnosis by laryngoscopy during symptomatic episode

9. Medications

9.1 Beta-2 Agonists

SABAs (Short-Acting):

Albuterol (salbutamol): onset 3-5 min, duration 4-6 h; MDI or nebulizer
Indicated for reliever (rescue) therapy
Regular use → tachyphylaxis of bronchoprotective effect; associated with increased mortality when used without ICS
β₂-receptor polymorphism at amino acid 16 → increased airway reactivity with regular SABA use

LABAs (Long-Acting, ~12h):

Salmeterol (slow onset), Formoterol (rapid onset, comparable to SABA)
NEVER use as monotherapy in asthma (increased mortality risk)
Always combine with ICS

Ultra-Long-Acting (24h):

Indacaterol, olodaterol, vilanterol
Only used in combination with ICS in asthma

Side effects: Tremor, tachycardia, palpitations, hypokalemia (promotes K⁺ re-entry into cells), Type B lactic acidosis (via increased glycogenolysis, glycolysis, lipolysis → fatty acids inhibit pyruvate → acetyl-CoA conversion)

9.2 Inhaled Corticosteroids (ICS)

Mechanism: Reduce type 2 inflammation and AHR; bind cytoplasmic glucocorticoid receptors → inhibit gene transcription of inflammatory cytokines

Agents (in increasing potency/low oral bioavailability order):

Beclomethasone (dipropionate) - older, 20% oral bioavailability
Budesonide - moderate bioavailability, safe in pregnancy
Fluticasone propionate - ~1% oral bioavailability
Mometasone - <1% oral bioavailability
Fluticasone furoate - ultra-LABA combination (vilanterol)
Ciclesonide - pro-drug, activated only in lung tissue, minimal systemic effects

9.3 Anticholinergics (Muscarinic Antagonists)

SAMA (ipratropium): Used for acute severe asthma (combined with SABA in emergency)
LAMA (tiotropium): Add-on therapy at Step 4-5; can be used instead of LABA in some patients
ICS/LAMA approved for asthma in adults; some concern of numerical (not significant) increased mortality in African Americans vs ICS/LABA

9.4 Leukotriene Receptor Antagonists (LTRAs)

Montelukast, zafirlukast, pranlukast
Alternative controller at Step 2; useful for aspirin-exacerbated disease and exercise-induced asthma
⚠️ FDA black box warning: Montelukast associated with serious neuropsychiatric effects including suicidal ideation - this limits use as first-line alternative

9.5 Theophylline

Now rarely used due to narrow therapeutic window, drug-drug interactions, and reduced bronchodilation vs other agents
Occasionally used as add-on in Step 4-5 in resource-limited settings

9.6 Anti-IgE Therapy

Omalizumab (anti-IgE monoclonal antibody): for moderate-severe allergic asthma; eligibility - perennial allergen sensitization, elevated total IgE
Reduces exacerbations, emergency visits, steroid use
GINA 2026: also approved for CRSwNP (along with omalizumab-igec biosimilar)

9.7 Anti-IL-5 / Anti-IL-5Rα

Mepolizumab (anti-IL-5): SC, every 4 weeks; blood eosinophils ≥150-300/µL
Reslizumab (anti-IL-5): IV, weight-based; blood eosinophils ≥400/µL
Benralizumab (anti-IL-5Rα): SC, every 4 weeks (then every 8 weeks); produces near-complete eosinophil depletion; blood eosinophils ≥300/µL
Depemokimab (NEW - GINA 2026): approved for severe eosinophilic asthma ≥12 years; also approved for CRSwNP ≥18 years; long-acting biologic

9.8 Anti-IL-4Rα

Dupilumab: Blocks both IL-4 and IL-13 signaling; for moderate-severe eosinophilic/type 2 asthma; also effective for CRSwNP and atopic dermatitis (addresses "one airway, one disease")

9.9 Anti-TSLP

Tezepelumab: Anti-TSLP (targets most upstream alarmin); effective even in patients without classic T2 biomarkers; broad efficacy across phenotypes including non-eosinophilic asthma; GINA 2026 includes it in CRSwNP indication

10. Stepwise Management (GINA 2026 / NAEPP Framework)

Key Paradigm Shift - Anti-Inflammatory Reliever (AIR)

A landmark change: ICS/formoterol (single inhaler) used as-needed for relief - instead of SABA alone - is now the preferred approach at all steps. This reduces severe exacerbations and OCS use by ensuring anti-inflammatory therapy accompanies every bronchodilator dose.

Step	Preferred Therapy	Alternative
Step 1 (Intermittent)	As-needed low-dose ICS/formoterol (AIR)	As-needed ICS + SABA (NAEPP); As-needed SABA alone (if AIR unavailable)
Step 2 (Mild persistent)	Low-dose ICS daily + as-needed ICS/formoterol (AIR)	Low-dose ICS daily + SABA; LTRA (but monitor for neuropsychiatric effects)
Step 3 (Moderate persistent)	Low-dose ICS/LABA daily + as-needed ICS/formoterol	Medium-dose ICS; LTRA add-on
Step 4 (Severe)	Medium-dose ICS/LABA daily + as-needed ICS/formoterol	Add LAMA; add LTRA or theophylline
Step 5 (Very severe/uncontrolled)	High-dose ICS/LABA + LAMA + biologic therapy (anti-IgE, anti-IL-5, anti-IL-4Rα, anti-TSLP)	Minimal oral corticosteroids (minimize OCS due to side effects)

Biologic Selection at Step 5 (GINA 2026 Decision Tree):

Based on: Type 2 biomarkers (FeNO, blood eosinophils, IgE), comorbidities (AERD, CRSwNP, atopic dermatitis), cost, dosing frequency, route of administration, patient preference
All biologics in GINA 2026 decision tree are for T2 inflammation

Stepping Up/Down:

Step UP after 2-3 months of poor control (rule out: poor adherence, poor technique, ongoing exposure, comorbidities first)
Step DOWN when well-controlled for ≥3 months (avoid discontinuing ICS entirely)

OCS Minimization (GINA 2026):

All patients must receive ICS-containing therapy
ICS/formoterol or ICS/SABA as AIR reduces the risk of severe exacerbations requiring OCS
Treat modifiable risk factors; improve inhaler technique; patient education

Poor adherence or poor inhaler technique accounts for up to 50% of cases referred for poorly controlled asthma - always address before stepping up.

11. Acute Severe Asthma (Asthma Attack)

Assessment of Severity

Feature	Moderate Attack	Severe Attack	Life-Threatening
Speech	Full sentences	Phrases	Words/unable
RR	20-25	25-30	>30
HR	<110	110-120	>120
PEFR	>50-75% best	33-50% best	<33% best ("brittle")
SpO₂	>95%	92-95%	<92%
Wheeze	Moderate	Loud	Silent chest (DANGER)
Mental status	Normal	Agitated	Drowsy/confused
PaCO₂	<45	<45	≥45 (impending respiratory failure)

⚠️ A normal or rising PaCO₂ in a severe asthma attack indicates fatigue and impending respiratory failure - prepare for intubation.

GINA 2026 - Acute Management

Mild-to-Moderate:

SABA (salbutamol 4-8 puffs via MDI with spacer OR nebulizer) up to every 1h
ICS/formoterol as AIR for mild exacerbations (alternative to SABA)
Increase maintenance ICS dose 4-5 fold
Oral corticosteroids if not responding

Severe:

Salbutamol up to 3 times, 20-30 min apart (GINA 2026 specifies dosing)
Ipratropium 4 puffs with salbutamol for up to 3 times
Oral/IV corticosteroids initiated
Supplemental oxygen (GINA 2026 updated SpO₂ targets)
IV magnesium sulfate 2g over 20 min for life-threatening/refractory cases
Heliox (helium-oxygen mixture) - reduces work of breathing in very severe cases
NIV may be considered in selected patients
ICU + intubation for respiratory failure (mechanical ventilation is challenging - increased risk of barotrauma, air-trapping, permissive hypercapnia strategy)

After Acute Attack:

Oral corticosteroids typically for 5-7 days
Increase controller therapy
Arrange early follow-up (within 1 week)
GINA 2026: updated discharge planning and follow-up protocols

12. Special Considerations

Asthma in Pregnancy

~4% of pregnant women have asthma; ~1/3 worsen during pregnancy
FEV₁ and PEFR unchanged in pregnancy (useful for monitoring)
Progesterone → increased tidal volume + minute ventilation (normal in pregnancy)
ABG in pregnancy: pH 7.45, PaCO₂ 27-32 mmHg (respiratory alkalosis = normal)
A normal PaCO₂ (40 mmHg) in a pregnant asthmatic = hypercapnia relative to normal pregnancy values
Moderate-severe asthma in pregnancy increases risk of preterm labor, low birth weight, perinatal death, preeclampsia
ICS are safe in pregnancy - undertreated asthma is far more dangerous to the fetus than ICS

Aspirin-Exacerbated Respiratory Disease (AERD)

Triad: asthma + nasal polyposis + hypersensitivity to aspirin/NSAIDs
Mechanism: Cyclooxygenase-1 inhibition → shunting of arachidonic acid toward leukotriene pathway
Nasal polyps in adults should raise suspicion
Management: Avoid NSAIDs; LTRAs (zafirlukast/montelukast) helpful; aspirin desensitization

Asthma-COPD Overlap (ACO)

Features of both asthma (reversibility, AHR, eosinophilia) and COPD (incomplete reversibility, smoking history, emphysema on CT)
Treatment is complex; ICS important; long-acting bronchodilators
SABA monotherapy alone is contraindicated

Occupational Asthma

Sensitizer-induced: develops after a latency period; caused by high MW (proteins) or low MW (chemicals like isocyanates) agents
Irritant-induced (RADS): after single, high-level irritant exposure; no latency period
Diagnosis: serial PEF measurements at work and away; specific bronchial challenge; reduction on vacation = diagnostic clue

13. Monitoring Parameters

Parameter	Use
Asthma Control Test (ACT)	Score ≤19 = uncontrolled; validated questionnaire
PEFR diary	Daily monitoring; diurnal variation >10% = poor control
FeNO	Follow T2 inflammation; guide ICS titration
Blood eosinophils	Monitor T2; guide biologic eligibility
Spirometry	Baseline, annual, or when control changes
CAAT (new in GINA 2026)	Chronic Airways Assessment Test
Peds-AIRQ / PRAM (new in GINA 2026)	Pediatric assessment tools

14. Fatality Risk Indicators (GINA 2026 - New Focus)

Risk factors for asthma death:

Previous near-fatal attack (intubation, ICU)
Hospitalization for asthma in past year
Currently not using ICS or poor adherence
Currently using or recently stopped OCS
Overuse of SABA (>1 canister/month)
No written asthma action plan
History of psychiatric illness or psychosocial problems
Food allergy with confirmed sensitization
Comorbid cardiovascular disease

15. Quick Reference Summary

ASTHMA = Episodic obstruction + AHR + Inflammation (usually eosinophilic)

Diagnosis: Symptoms + reversible obstruction on spirometry 
           OR positive bronchial provocation (PC20 <8 mg/mL)

T2 biomarkers: FeNO ≥40, eosinophils ≥300/µL, elevated IgE

Reliever (ALL steps): ICS/formoterol (AIR) - NOT SABA alone [GINA 2026]

Controller hierarchy:
Step 1-2: Low ICS ± LTRA
Step 3:   ICS/LABA
Step 4:   Medium ICS/LABA ± LAMA
Step 5:   Biologic (anti-IgE, anti-IL-5, anti-IL-4Rα, anti-TSLP)

Acute severe: SABA + ipratropium + OCS; Mg²⁺ for life-threatening
Silent chest + normal PaCO₂ = DANGER signs

Biologics (T2): Omalizumab, mepolizumab, reslizumab, benralizumab,
               dupilumab, tezepelumab, depemokimab (NEW 2026)

Key 2026 Updates:

ICS/formoterol as AIR at ALL steps (including Step 1) - reducing OCS need
New biologic: Depemokimab for severe eosinophilic asthma (≥12y) and CRSwNP (≥18y)
Updated fatality risk indicators - greater emphasis on prevention of asthma death
New assessment tools: CAAT, Peds-AIRQ, PRAM
Updated SpO₂ targets and SABA dosing in acute management
Biologic decision tree updated for T2 inflammation with comorbidity consideration

Sources: Harrison's Principles of Internal Medicine 22E (2025), Murray & Nadel's Textbook of Respiratory Medicine, Fishman's Pulmonary Diseases and Disorders, ICS pharmacology section (Murray & Nadel block 3), GINA 2026 Global Strategy Report (released May 5, 2026)

Tell me detail about asthma

I just provided a very detailed, comprehensive guide on Asthma in the previous response - tailored for a 1st year Respiratory Medicine PGT. It covers everything you need:

Definition & Epidemiology
Pathophysiology - Type 2 vs Non-Type 2 inflammation, airway remodeling, AHR mechanisms, with the airway cross-section diagram
ICS Pharmacology - oral bioavailability comparison, systemic effects
Classification - phenotypes (allergic, eosinophilic, AERD, obesity-associated, neutrophilic, occupational)
Triggers - allergens, viral infections, drugs (beta-blockers, aspirin, ACE inhibitors), exercise, pollution
Clinical Features - symptoms, physical exam, control assessment table
Diagnosis - spirometry, PEFR, bronchial provocation (PC20), FeNO, blood eosinophils, skin testing
Comorbidities - rhinosinusitis, GERD, obesity, OSA, vocal cord dysfunction, anxiety
Medications - SABAs, LABAs, ICS (agents + bioavailability), LAMAs, LTRAs (montelukast warning), theophylline, all biologics
Stepwise Management (GINA 2026) - including the AIR (Anti-Inflammatory Reliever) paradigm shift
Acute Severe Asthma - severity grading table, management protocol, danger signs
Special Situations - pregnancy, AERD, ACO, occupational asthma
GINA 2026 Key Updates - depemokimab, new assessment tools, fatality risk indicators

Please scroll up to review that full answer. If you'd like me to go deeper on any specific section - for example, biologic selection criteria, acute asthma ABG interpretation, spirometry patterns, AERD management, or asthma in pregnancy - just ask and I'll expand on that specific topic.

More detail

Asking for Preferences

Finding Sources

Searching PubMed

"severe asthma" AND "biologic therapy"

Searching the Web

asthma pathophysiology immunology type 2 inflammation T2 non-T2 endotypes 2025 2026

Finding Sources

Reading File

Loading Image

Reading File

I now have extremely deep mechanistic content. Let me now compile the comprehensive extended deep-dive answer:

ASTHMA - Deep Dive (Extended PGT Reference)

Compiled from Harrison's Principles of Internal Medicine 22E (2025), Goodman & Gilman's Pharmacological Basis of Therapeutics, Cellular and Molecular Immunology (Abbas), Murray & Nadel's Respiratory Medicine, Fishman's Pulmonary Diseases, GINA 2026

PART 1: EPIDEMIOLOGY (in depth)

~262 million people affected globally (Harrison's 2025)
US prevalence: 7.9% (vs ~4.3% worldwide); has been rising since 2001 (was 7.3%)
More common in children (8.4%) than adults (7.7%)
Children: 2:1 male > female ratio
Adults: female > male (hormonal influence)
Highest US prevalence: Puerto Rican population; highest morbidity in Black race
1.8 million US ED visits/year; 189,000 hospitalizations (2016 data)
Total US economic cost: $82 billion (2013)
Asthma mortality: rose in 1960s (due to overuse of high-potency inhaled β₂-agonists); declined after 1990s with widespread ICS use; mortality rate declined from 0.44 per 100,000 (1993) to 0.19 (2006) - but no further reduction since then
COVID-19 pandemic → nearly 50% reduction in exacerbations (attributed to decreased viral infections from social distancing)

PART 2: PATHOGENESIS - FROM ALLERGEN TO AIRWAY (Molecular Detail)

2.1 The Asthma Development Pathway

GENETIC SUSCEPTIBILITY
        +
ENVIRONMENTAL EXPOSURES (allergens, pollution, infections, tobacco)
        +
DEVELOPMENTAL FACTORS (aging, hormonal changes, obesity)
        ↓
Airway Hyperresponsiveness
        +
Airway Inflammation (Type 2 or non-Type 2)
        +
Structural Changes (Remodeling)
        ↓
ASTHMA (symptoms ← triggers → exacerbations)

2.2 The Allergic (IgE-mediated) Cascade

Sensitization phase:

Allergen enters airway mucosa
Captured by dendritic cells → processed → presented via MHCII to naive T-cells
In atopic individuals → Th2 polarization (master transcription factor: GATA-3)
Th2 cells produce: IL-4 (drives B-cell class switching to IgE), IL-5 (eosinophil survival/activation), IL-13 (mucus production, AHR, IgE)
B-cells produce IgE antibodies → bind to FcεRI receptors on mast cells and basophils

Effector phase (re-exposure):

Allergen cross-links surface-bound IgE on mast cells
Mast cell degranulation → rapid release of preformed mediators (within minutes)
New mediator synthesis occurs over hours

2.3 Mast Cell - The Central Effector Cell

Mast cell/basophil-mediated asthma: Mediators, mechanisms and therapeutic targets. From Cellular and Molecular Immunology (Abbas).

Preformed mediators (released within minutes of activation):

Mediator	Effect
Histamine	Smooth muscle contraction, vasodilation, increased vascular permeability, mucus secretion
Tryptase	Protease; activates complement, kinin, coagulation pathways; marker of mast cell activation
Heparin	Anti-coagulant; potentiates tryptase

Newly synthesized lipid mediators (via arachidonic acid pathway, over hours):

Mediator	Pathway	Effect
LTC₄ → LTD₄ → LTE₄ (cysteinyl leukotrienes)	5-lipoxygenase (5-LO)	Major mediators of bronchoconstriction (1000x more potent than histamine); vascular permeability, mucus secretion
LTB₄	5-LO	Neutrophil chemotaxis
PGD₂ (Prostaglandin D₂)	COX pathway	Bronchoconstriction, vasodilation, eosinophil/basophil recruitment via CRTH2 receptor
PAF (Platelet-Activating Factor)	Phospholipase A₂	Bronchoconstriction, platelet aggregation, eosinophil recruitment
Thromboxane A₂	COX pathway	Bronchoconstriction, vasoconstriction

Cytokines (sustained inflammation - the LATE PHASE RESPONSE):

Cytokine	Source	Effect
IL-4	Mast cells, Th2	IgE class switching; upregulates VCAM-1 (eosinophil trafficking)
IL-5	Mast cells, Th2, ILC2	Eosinophil maturation (bone marrow), survival, activation
IL-13	Mast cells, Th2, ILC2	Mucus hypersecretion (goblet cell metaplasia), AHR, IgE production, airway remodeling
TNF-α	Mast cells, macrophages	Pro-inflammatory, NF-κB activation, adhesion molecule upregulation

Biphasic Response: The initial bronchoconstriction (early asthmatic response, EAR) reflects histamine, PG, and leukotriene effects. The late-phase reaction (LAR, 4-6h later) is cytokine/eosinophil-mediated sustained inflammation. Corticosteroids suppress the late phase but NOT the early phase. LTRAs suppress BOTH phases.

2.4 The Alarmin Cascade (Innate Immunity - Critical for PGT)

Airway epithelial cells, when damaged by allergens, pollutants, or infections, release alarmins:

Alarmin	Source	Downstream Effect
TSLP (Thymic Stromal Lymphopoietin)	Epithelium	Activates dendritic cells → Th2 polarization; activates ILC2s; stimulates mast cells; promotes neutrophilic inflammation (T2-low path)
IL-25 (IL-17E)	Epithelium, eosinophils	Activates ILC2s → IL-4, IL-5, IL-13 production
IL-33	Epithelium, smooth muscle	Activates ILC2s and mast cells → IL-5, IL-13; amplifies T2 inflammation

ILC2s (Innate Lymphoid Cells type 2) can drive T2 inflammation without allergen sensitization - this explains non-allergic eosinophilic asthma. TSLP is the most upstream alarmin and the broadest therapeutic target (tezepelumab).

2.5 Eosinophil in Asthma

Eosinophils are recruited via:

IL-5 (differentiation from bone marrow progenitors)
Eotaxins (CCL11, CCL24, CCL26) via CCR3 receptor on eosinophils
VCAM-1 on endothelium (upregulated by IL-4)

Eosinophil mediators causing airway damage:

Product	Effect
MBP (Major Basic Protein)	Toxic to epithelium; causes epithelial shedding; directly induces AHR
ECP (Eosinophil Cationic Protein)	Toxic to epithelium and parasites; induces mast cell histamine release
EPO (Eosinophil Peroxidase)	Oxidative damage via H₂O₂ + halide
EDN (Eosinophil-Derived Neurotoxin)	Ribonuclease; neurotoxic; AHR
Cysteinyl leukotrienes (LTC₄)	Bronchoconstriction, mucus secretion
IL-5, IL-13	Perpetuates T2 inflammation

Eosinophils also cause peribronchiolar collagen deposition (subepithelial fibrosis) - the histological hallmark of asthma - present even at disease onset.

2.6 Type 2 vs Non-Type 2 Detailed Comparison

Feature	T2-High	T2-Low (Neutrophilic)	T2-Low (Paucigranulocytic)
Frequency	~50-70%	~20-30%	~10-20%
Inflammatory cells	Eosinophils + mast cells	Neutrophils	None predominant
Key cytokines	IL-4, IL-5, IL-13, TSLP, IL-33, IL-25	IL-17A, IL-17F, IL-8 (CXCL8)	Unclear
Driving cells	Th2 + ILC2	Th17 + ILC3	Smooth muscle intrinsic
Blood eosinophils	≥150-300/µL	Normal/low	Normal
FeNO	≥25-40 ppb	Low (<25 ppb)	Low
Serum IgE	Often elevated	Normal	Normal
ICS response	Excellent	Poor (steroid-resistant)	Variable
Associated with	Atopy, allergic rhinitis, early-onset	Smoking, obesity, infection, neutrophil-driven	Smooth muscle-predominant
Periostin	Elevated (esp. AERD)	Low	Low
Treatment	ICS, biologics (anti-IgE, anti-IL-5, anti-IL-4Rα, anti-TSLP)	LAMA, bronchial thermoplasty, treat triggers	ICS + LABA; bronchial thermoplasty

2.7 Airway Remodeling (Structural Changes)

All structural changes are driven by chronic eosinophilic inflammation and epithelial-mesenchymal interactions:

Change	Mechanism	Clinical Consequence
Goblet cell hyperplasia	IL-13, IL-5	Mucus hypersecretion → mucus plugging
Submucosal gland hypertrophy	Cholinergic stimulation, IL-13	Increased mucus volume
Subepithelial fibrosis	Myofibroblast activation → collagen (types I, III, V), tenascin, periostin, fibronectin, osteopontin	Airway wall stiffening → irreversible obstruction component
Smooth muscle hypertrophy + hyperplasia	Growth factors (EGF, PDGF, bFGF)	Increased contractile mass → AHR
Angiogenesis	VEGF (from eosinophils, mast cells, epithelium)	Airway edema; supports inflammatory cell trafficking
Epithelial shedding	MBP, EPO damage	Exposes sub-epithelial sensory nerves → AHR; forms epithelial-mesenchymal trophic unit
Neuronal remodeling	Nerve growth factor, substance P	Enhanced sensory nerve activity → cough, bronchoconstriction
Lymphatic remodeling	Decreased lymphatic density in fatal asthma despite elevated VEGF-C/D	Airway edema → worsened obstruction

Remodeling begins early - subepithelial fibrosis is found even at disease onset. Corticosteroids suppress inflammation but do NOT consistently reverse remodeling. This is why prevention of progression is critical.

PART 3: GENETICS & RISK FACTORS

Genetic Factors

Asthma has strong genetic heritability (~60-80% in twins)
Candidate genes cluster around:
- Chromosome 5q31-33: IL-4, IL-5, IL-13, IL-9, GM-CSF gene cluster; β₂-adrenergic receptor
- Chromosome 11q13: FcεRI β-chain (high-affinity IgE receptor)
- Chromosome 12q: IFN-γ, stem cell factor, IGF
- Chromosome 13q: BRCA2, IgE regulation
- ORMDL3/GSDMB (chromosome 17q21): one of the strongest GWAS associations for childhood asthma
β₂-receptor polymorphism at amino acid 16 (Arg→Gly): Gly/Gly homozygotes show greater tachyphylaxis with regular SABA use and increased AHR

Risk Factors for Development

Factor	Mechanism
Allergen exposure in atopic individuals	IgE sensitization
Viral infections (RSV, rhinovirus in infancy)	Persistent AHR; may initiate asthma trajectory
Tobacco exposure (active + passive)	Airway inflammation, impaired mucociliary clearance
Air pollution	Oxidative stress, airway inflammation; ozone, NO₂, PM₂.₅
Obesity	Altered lung mechanics; non-T2 inflammation; leptin effects; adipokines
Diet (Western diet, reduced antioxidants)	Increased oxidative stress; altered microbiome
Low vitamin D	Reduced regulatory T-cell function
Antibiotics in infancy	Altered gut microbiome (hygiene hypothesis)
Hygiene hypothesis	Reduced microbial exposure → failure to develop Th1 immunity → unopposed Th2 → atopy
Elite athletes (high-intensity exercise)	Repeated airway desiccation/osmotic stress

PART 4: DIAGNOSIS IN DETAIL

4.1 Pulmonary Function Testing

Spirometry interpretation in asthma:

Finding	Significance
FEV₁/FVC <0.70 (or <LLN)	Obstructive pattern
Post-BD FEV₁ increase ≥12% AND ≥200 mL	Significant reversibility = confirms asthma
Near-normal FEV₁ between attacks	Mild asthma - spirometry alone may miss diagnosis
Low FEV₁	Strong predictor of future exacerbations and decline in control
PEF variability >10% (am vs pm)	Suggests poor asthma control
PEF variability	Better predictor of future exacerbations than single PEF measurement

Important caveats:

FEV₁ may be normal or near-normal in mild asthma - does NOT exclude the diagnosis
Diagnosis may be difficult to confirm after starting ICS (obstruction and AHR mitigate with therapy) - if diagnosis uncertain, trial of medication taper may be needed
Low FEV₁ = strongest objective predictor of poor asthma control and need for acute care

4.2 Bronchial Provocation Testing

Methacholine Challenge (Direct AHR):

Direct smooth muscle stimulation via M₃ muscarinic receptors
PC₂₀ <8 mg/mL = significant AHR (positive test)
False positives: COPD, allergic rhinitis, heart failure, recent viral URTI (persists 4-6 weeks)
If FEV₁ normal → use PC₂₅ for impairment rating

Exercise Challenge (Indirect AHR):

Hyperventilation → airway desiccation → osmolarity change in lining fluid → mediator release
>10-15% fall in FEV₁ post-exercise = positive
More specific for exercise-induced bronchoconstriction

Mannitol Challenge (Indirect AHR):

Osmotic challenge - desiccates airway surface → mediator release
Positive: ≥15% fall in FEV₁ at cumulative dose ≤635 mg
Better specificity than methacholine for confirming active asthma

4.3 FeNO Interpretation

FeNO Level	Interpretation	Action
<25 ppb	Low - eosinophilic inflammation unlikely	ICS response less likely; consider non-T2
25-50 ppb	Borderline	Consider clinical context
≥40-50 ppb	High - eosinophilic T2 inflammation	Strong ICS response expected; biologic eligibility

FeNO is driven primarily by IL-13 → inducible NO synthase in airway epithelium
Elevated in eosinophilic asthma, AERD, allergic rhinitis
Falls with ICS - useful for monitoring adherence and adjusting dose
NOT affected by acute bronchodilators
Smoking falsely LOWERS FeNO
Tall height and atopy increase FeNO

4.4 Sputum Eosinophil Count

Eosinophils >2-3% = eosinophilic asthma; predicts ICS response and exacerbation risk
Gold standard for T2 phenotyping but invasive; mainly used in research/specialist centres
Useful to guide ICS dose titration in severe asthma (reduces exacerbations better than symptom-guided titration)

4.5 Blood Eosinophil Count (BEC)

BEC	Interpretation
≥150/µL	Suggests T2 inflammation; threshold for some biologic eligibility criteria
≥300/µL	Strong T2 signal; preferred threshold for mepolizumab, benralizumab eligibility
≥400/µL	Reslizumab eligibility threshold
>1500/µL	Hypereosinophilic syndrome territory - check for other causes

4.6 Differential Diagnosis

Condition	Key Distinguishing Feature
COPD	Smoking history; incomplete reversibility; FEV₁/FVC <0.70 post-BD; no significant atopy
Heart failure	Orthopnoea, PND, elevated BNP, basal crackles, dilated heart on CXR
Vocal cord dysfunction (ILO)	Inspiratory stridor; laryngoscopy-confirmed; resolves with speech therapy
Bronchiectasis	Chronic productive cough; finger clubbing; CT bronchial dilation + wall thickening
α₁-antitrypsin deficiency	Panlobular emphysema; liver disease; family history; measured levels
Bronchiolitis obliterans	Fixed obstruction; mosaic attenuation on HRCT; history of infection/transplant
Hyperventilation syndrome	Paraesthesias, tetany; normal spirometry; ETCO₂ low
Foreign body	Unilateral wheeze; history
Carcinoid / endobronchial mass	Fixed wheeze; stridor; CT/bronchoscopy

PART 5: PHARMACOLOGY - MOLECULAR MECHANISMS

5.1 β₂-Agonist Mechanism (Molecular Detail)

Activation pathway:

β₂ receptor → Gs protein → Adenylyl cyclase 
→ ↑cAMP → Protein Kinase A (PKA) activation
→ Phosphorylation of:
   • Myosin light chain kinase (MLCK) → inhibited → smooth muscle RELAXATION
   • K+ channels (Ca²⁺-activated K+) → opens → hyperpolarization → relaxation
   • Decreased PI hydrolysis (↓IP₃ → ↓intracellular Ca²⁺)
   • Increased Na⁺/K⁺-ATPase activity
   • Increased myosin light chain phosphatase activity

Additional β₂-agonist effects beyond bronchodilation:

Inhibit mast cell mediator release (via β₂ on mast cells)
Prevent microvascular leakage (reduce edema from histamine/LTD₄/PGD₂)
Increase mucociliary clearance (enhance ion transport + mucus secretion from submucosal glands)
Inhibit ACh release from presynaptic β₂ receptors on cholinergic nerves

Why SABA monotherapy is dangerous in asthma:

β₂-agonists are functional antagonists (relieve symptoms) but have NO anti-inflammatory effect
Regular SABA use → tachyphylaxis of bronchoprotective effect
Arg16 polymorphism patients: regular SABA → increased airway reactivity
Increased SABA use = marker of poor control = associated with increased asthma mortality
Hence GINA 2026 mandates ICS/formoterol as AIR (not SABA alone)

Why formoterol can be used as reliever but salmeterol cannot:

Formoterol: moderate lipophilicity → stays near membrane receptor → slow-release property → but in plasma, loses this → can act rapidly; onset comparable to SABA (3-5 min)
Salmeterol: long aliphatic chain anchored in receptor "exosite" → cannot dissociate rapidly → slow onset → NOT suitable as reliever

5.2 ICS Mechanism (Molecular Detail)

ICS molecule → enters cell → binds cytoplasmic glucocorticoid receptor (GR)
→ GR-ICS complex translocates to nucleus
→ Two mechanisms:

1. Trans-repression (anti-inflammatory - main effect):
   Binds to NF-κB and AP-1 transcription factors
   → Inhibits expression of inflammatory genes:
     (IL-4, IL-5, IL-13, TNF-α, ICAM-1, Cox-2, iNOS)
   → Reduces FeNO, eosinophil counts, AHR

2. Trans-activation (side effects - via GRE binding):
   Upregulates anti-inflammatory proteins (annexin-1, SLPI)
   → Also responsible for: growth suppression, bone loss, cataracts, skin thinning

ICS clinical features by agent:

Drug	Oral Bioavailability	Half-life	Special Feature
Beclomethasone (BDP)	~20%	~0.5h (activated to 17-BMP in lung)	Oldest; oropharyngeal deposition issue
Budesonide	~10-15%	2-3h	Safe in pregnancy; both pMDI and DPI
Fluticasone propionate	~1%	14h	High topical potency; low oral BA
Fluticasone furoate	Negligible	24h	Once-daily; used with vilanterol
Mometasone	<1%	5h	Very low oral BA
Ciclesonide	<1%	0.7h (parent); 45h (active metabolite)	Pro-drug activated in lung by esterases; no oropharyngeal deposition; minimal systemic effects

5.3 ICS Resistance

Seen in severe asthma, especially T2-low/neutrophilic:

Reduced GR expression in inflammatory cells
GR-β isoform (acts as dominant negative inhibitor of GR-α)
NF-κB/AP-1 overactivation (overcomes steroid suppression)
HDAC2 (histone deacetylase 2) reduction - required for ICS to work; reduced by oxidative stress (smoking, severe asthma)
Macrophage-predominant neutrophilic inflammation - inherently ICS-resistant

5.4 Anticholinergic Mechanism

Cholinergic nerve stimulation → ACh release → M₃ receptor on smooth muscle
→ ↑IP₃ → ↑Ca²⁺ → smooth muscle CONTRACTION

Anticholinergics (SAMA/LAMA) → M₃ receptor blockade → smooth muscle RELAXATION

Less effective than β₂-agonists as bronchodilators (ACh is only one bronchoconstrictor pathway)
Also block M₃ receptors on submucosal glands → reduce mucus secretion
M₂ receptors (presynaptic, autoinhibitory) - if blocked → increased ACh release (pro-constrictive)
Tiotropium (LAMA): preferential M₃/M₁ kinetics → functional selectivity despite non-selective binding

5.5 Leukotriene Pathway and LTRAs

Arachidonic acid → 5-lipoxygenase (5-LO) + 5-LO activating protein (FLAP)
→ LTA₄ → LTC₄ (via glutathione-S-transferase)
→ secreted → cleaved to LTD₄ → LTE₄

All bind CysLT₁ receptor on smooth muscle, mucus glands, inflammatory cells
→ Bronchoconstriction + mucus hypersecretion + eosinophil recruitment + vascular permeability

LTRA (montelukast, zafirlukast) → CysLT₁ receptor antagonism
→ Reduces: early AND late phase response, exercise-induced bronchoconstriction,
   aspirin-triggered bronchoconstriction (AERD), nasal polyp growth

Leukotrienes are 1000x more potent than histamine as bronchoconstrictors. LTD₄ = most potent. FDA black box warning on montelukast (2020): serious neuropsychiatric events including suicidal ideation, depression, nightmares, aggression - must inform patients before prescribing.

PART 6: BIOLOGICS - FULL MECHANISTIC GUIDE

6.1 Overview - How Biologics Target T2 Inflammation

All current approved biologics for asthma target the T2 inflammatory cascade:

Allergen/Damage
     ↓
EPITHELIUM → TSLP → [Tezepelumab]
             IL-33 → [Itepekimab (in trials)]
             IL-25
     ↓
ILC2 / Th2
     ↓
IL-4  → IgE class switch → IgE → [Omalizumab / Omalizumab-igec]
IL-5  → Eosinophil maturation/survival → [Mepolizumab, Reslizumab]
                              ↓ IL-5Rα → [Benralizumab, Depemokimab]
IL-13 → Mucus, AHR, fibrosis
 ↕
IL-4Rα (shared receptor subunit for IL-4 and IL-13) → [Dupilumab]

6.2 Individual Biologics

Biologic	Target	Route/Frequency	Blood Eos Threshold	Key Features
Omalizumab	IgE	SC q2-4 weeks	Not required (IgE-based)	Serum IgE 30-700 IU/mL + perennial allergen sensitization; reduces exacerbations ~25-50%; also for CRSwNP, urticaria
Omalizumab-igec	IgE (biosimilar)	SC q2-4 weeks	Not required	New in GINA 2026; biosimilar of omalizumab; now approved for CRSwNP
Mepolizumab	IL-5	SC 100 mg q4 weeks	≥150/µL (screen); ≥300/µL preferred	Reduces exacerbations ~50%; reduces OCS use; also for EGPA, HES, CRSwNP
Reslizumab	IL-5	IV weight-based q4 weeks	≥400/µL	Only IV biologic; reduces exacerbations ~50%
Benralizumab	IL-5Rα	SC 30mg q4 weeks ×3, then q8 weeks	≥300/µL	Near-complete blood eosinophil depletion (depletes via ADCC); also for CRSwNP
Dupilumab	IL-4Rα (blocks IL-4 + IL-13)	SC q2 weeks	≥150/µL or FeNO ≥25 ppb	Broadest T2 coverage; also atopic dermatitis, CRSwNP, eosinophilic esophagitis, COPD with eos; arthralgia side effect
Tezepelumab	TSLP	SC q4 weeks	None required	Broadest efficacy including T2-low/paucigranulocytic; upstream target; reduces exacerbations even with low eos/FeNO; also for CRSwNP
Depemokimab	IL-5 (long-acting)	SC q6 months	≥300/µL	NEW (GINA 2026); longest dosing interval of any biologic; ≥12y for eos asthma; ≥18y for CRSwNP

Biologic selection algorithm (simplified from GINA 2026):

Step 5 Severe Asthma - Need Biologic?
        ↓
Check T2 biomarkers (blood eos, FeNO, IgE, allergen sensitization)
        ↓
If ALLERGIC + elevated IgE → Omalizumab (or omalizumab-igec)
If EOSINOPHILIC (eos ≥300) → Anti-IL-5: Mepolizumab / Benralizumab / Reslizumab / Depemokimab
If EOSINOPHILIC + ATOPIC DERMATITIS/CRSwNP → Dupilumab (addresses "one airway" disease)
If BROAD T2 or UNCERTAIN or T2-LOW with eos → Tezepelumab (upstream, broadest)
If ALL T2 POSITIVE → Choose based on comorbidities, cost, route, frequency, patient preference

Evidence (Recent Systematic Review, PMID 40520782, 2025): Umbrella review of biologics for severe asthma confirms all approved biologics significantly reduce exacerbation rates, OCS use, and improve quality of life in T2 phenotypes. No single biologic is superior across all outcomes; selection should be individualized.

PART 7: GINA 2026 STEPWISE MANAGEMENT - FULL TABLE

Step	Preferred Controller	Preferred Reliever	Notes
Step 1 (Symptoms <2/month)	As-needed low-dose ICS-formoterol	ICS-formoterol (AIR)	Alternative: Low-dose ICS taken whenever SABA taken (NAEPP); SABA alone only if no ICS access
Step 2 (Symptoms ≥2/month, not daily)	Low-dose ICS daily OR as-needed low-dose ICS-formoterol	ICS-formoterol (AIR)	Alternative: LTRA or low-dose ICS taken with SABA
Step 3 (Daily symptoms)	Low-dose ICS/LABA	ICS-formoterol (AIR)	Alternative: medium-dose ICS; low-dose ICS + LTRA
Step 4 (Daily symptoms, uncontrolled on Step 3)	Medium-dose ICS/LABA	ICS-formoterol (AIR)	Add-on: LAMA (tiotropium); add-on LTRA
Step 5 (Uncontrolled on Step 4)	High-dose ICS/LABA + phenotypic assessment → biologic	ICS-formoterol (AIR)	Options: anti-IgE, anti-IL-5/5Rα, anti-IL-4Rα, anti-TSLP; Add low-dose OCS as last resort (side effects)

Stepping decisions:

Step UP: If poorly controlled for ≥2-3 months; FIRST check: adherence, inhaler technique, trigger avoidance, comorbidities
Step DOWN: When well-controlled for ≥3 months; do NOT fully stop ICS (risk of rebound)
Never stop ICS suddenly in any patient at any step

PART 8: STATUS ASTHMATICUS - DEEP ICU MANAGEMENT

8.1 Definition

Status asthmaticus = severe acute asthma not responding to initial bronchodilator therapy; near-fatal or life-threatening attack.

8.2 Pathophysiology of Acute Attack

Bronchoconstriction + airway edema + mucus plugging
↓
Air trapping → dynamic hyperinflation
↓
↑ Intrinsic PEEP (auto-PEEP) → increased work of breathing
↓
Respiratory muscle fatigue → Hypercapnia (DANGER)
↓
Respiratory failure → Cardiorespiratory arrest

ABG Evolution in Acute Severe Asthma:

Stage	PaO₂	PaCO₂	pH	Interpretation
Early/mild	Normal or ↓	↓ (hypocapnia)	↑ (alkalosis)	Tachypnea compensates; hyperventilation
Moderate	↓	Normal (~40)	Normal	DANGER: Normal PaCO₂ in distress = fatigue
Severe	↓↓	↑	↓ (acidosis)	Respiratory failure - intubate

Key exam point: A "normal" PaCO₂ in an acutely distressed asthmatic indicates impending respiratory failure. Most asthmatics should be hypocapnic during an attack.

8.3 Emergency Management Protocol

Immediate (0-20 min):

Supplemental O₂ to maintain SpO₂ 93-95% (GINA 2026 specifies updated SpO₂ targets; avoid hyperoxia)
Salbutamol (albuterol) via MDI+spacer (4-8 puffs) OR nebuliser - repeat every 20 min up to 3 times
Ipratropium bromide 4-8 puffs via MDI OR 0.5 mg nebulised - with each salbutamol dose (up to 3 times)
Systemic corticosteroids: Oral prednisolone 40-50 mg OR IV hydrocortisone 100-200 mg if cannot swallow; onset of effect 4-6h

If not responding (1-2h): 5. IV Magnesium Sulfate 2g over 20 min (single dose) - inhibits smooth muscle contraction by competing with Ca²⁺; reduces hospitalization and intubation in severe/life-threatening asthma 6. IV Salbutamol (in severe, refractory cases): continuous infusion 7. Consider IV aminophylline (theophylline prodrug) as add-on - narrow therapeutic window; use only with monitoring; rarely used now 8. BiPAP/HFNC (Non-invasive ventilation): Well tolerated in status asthmaticus; decreases need for intubation and ICU/hospital length of stay; preferred over intubation if patient is cooperative 9. Heliox (60:40 He:O₂ mixture): Reduces airway turbulence (helium is less dense than nitrogen); decreases work of breathing; allows better bronchodilator deposition; use while preparing for intubation

Intubation (last resort):

Indications: Impending/actual respiratory failure, deteriorating mental status, PaCO₂ rising + acidosis, silent chest, exhaustion
Challenges: High airway resistance → high peak pressures → risk of barotrauma, pneumothorax
Mechanical ventilation strategy:
- Low respiratory rate (RR 8-12/min) + low tidal volume (6-8 mL/kg IBW)
- Long expiratory time (I:E ratio 1:3 or 1:4) to minimize auto-PEEP and air trapping
- Permissive hypercapnia: Allow PaCO₂ to rise (accept pH ≥7.2); correct severe acidosis with sodium bicarbonate if pH <7.2
- Neuromuscular paralysis (short-term) to reduce peak airway pressures
- Ketamine as induction agent: bronchodilator properties via catecholamine release; drug of choice for intubation in severe asthma
- Volatile anaesthetic agents (isoflurane, sevoflurane): potent bronchodilators; use in refractory cases at specialist centres; associated with increased ventilator length in some studies
- Bronchoscopy to clear mucus plugs: described but potentially dangerous during difficult MV; reserved for selected cases

8.4 Asthma Mortality Risk Factors (Harrison's 2025)

Patients with any of these require intensive monitoring and admission:

History of ICU admission for asthma
History of intubation for asthma
Illicit drug use
Depression
New diagnosis within past year
≥2 ED visits in past 6 months
Severe psychosocial problems
Lower socioeconomic status
≥2 courses of systemic corticosteroids in past year
Overuse of SABAs (>1 canister/month)
Currently not on ICS or non-adherent

PART 9: SPECIAL SCENARIOS (Detailed)

9.1 Exercise-Induced Bronchoconstriction (EIB)

Mechanism:

Exercise → hyperventilation → desiccation of airway lining fluid → osmolarity change in airway surface liquid → mast cell degranulation → mediator release (LTs, PGs, histamine) → bronchoconstriction
Cold air compounds this (lower absolute moisture; rewarming also causes edema)
EIB usually peaks 5-15 minutes after exercise and resolves 30-60 min spontaneously

Diagnosis:

10-15% fall in FEV₁ within 15-30 min of standardized exercise challenge
Distinguish from refractory period (2h window after exercise where subsequent exercise causes less bronchoconstriction - related to mast cell mediator depletion)

Management:

ICS (long-term anti-inflammatory - reduces mast cell activity)
Pre-treatment: SABA 15-20 min before exercise; or ICS/formoterol (single dose)
LABAs for occasional exercise: can extend bronchoprotection but NOT recommended for monotherapy
Warm-up exercises before vigorous activity (exploits refractory period)
Breathing through nose/warm scarf in cold weather

9.2 Aspirin-Exacerbated Respiratory Disease (AERD)

Mechanism:

Aspirin/NSAID → COX-1 inhibition
↓
Arachidonic acid NOT converted to PGs (especially PGE₂ - bronchodilatory)
↓
Shunting → 5-LO pathway → overproduction of CysLTs
↓
Massive bronchoconstriction + rhinorrhoea + urticaria

Triad: Asthma + Nasal polyposis + Aspirin/NSAID hypersensitivity

Diagnosis: Aspirin oral challenge (gold standard); or aspirin-lysine inhalation challenge

Periostin is significantly elevated in AERD (mean 64.7 ng/mL) compared to other asthma endotypes

Management:

Avoid COX-1 inhibitors (aspirin, ibuprofen, naproxen, diclofenac, indomethacin)
Safe alternatives: Paracetamol (acetaminophen) at low doses; COX-2 selective inhibitors (celecoxib - use cautiously)
LTRAs (montelukast, zafirlukast) - reduce severity
Aspirin desensitization: Gradual incremental aspirin doses in supervised setting → tolerance; allows aspirin for cardiovascular disease; reduces polyp recurrence and systemic steroid need
Dupilumab and tezepelumab show efficacy for AERD-associated nasal polyps

9.3 Asthma-COPD Overlap (ACO)

Features (must have at least some of each):

Asthma features	COPD features
Variable symptoms	≥10 pack-year smoking history
Significant reversibility (≥15% post-BD)	FEV₁/FVC <0.70 post-BD
Blood eosinophilia / elevated FeNO	CT emphysema or air trapping
History of childhood asthma or atopy	Age >40

Management:

ICS are mandatory (reduces mortality in ACO vs ICS withdrawal)
LABA/LAMA as add-on
SABA as reliever
SABA monotherapy is contraindicated in ACO
Pulmonary rehabilitation for functional limitation
Manage comorbidities (cardiovascular disease, osteoporosis from long-term OCS)

PART 10: MONITORING FRAMEWORK (GINA 2026)

10.1 Asthma Control Questionnaires

Asthma Control Test (ACT):

5 questions covering past 4 weeks; scored 5-25
≤19 = poorly controlled; ≥20 = well controlled; 25 = fully controlled

Asthma Control Questionnaire (ACQ):

6-7 items; score 0-6; higher = worse control
Score >1.5 = uncontrolled; <0.75 = controlled

NEW in GINA 2026:

CAAT (Chronic Airways Assessment Test) - for patients with both asthma and COPD features
Peds-AIRQ (Pediatric Asthma Impairment and Risk Questionnaire)
PRAM (Pediatric Respiratory Assessment Measure) - for acute exacerbation severity in children

10.2 Written Asthma Action Plan

Every patient should have a written action plan
Based on symptoms or PEFR (green/yellow/red zones)
Specifies: when to increase reliever, when to start OCS, when to go to ED
Absence of written plan = fatality risk factor

PART 11: ASTHMA vs COPD at a Glance

Feature	Asthma	COPD
Age of onset	Often childhood	Usually >40y
Smoking	Usually not	Major cause
Atopy	Common	Uncommon
Inflammation	Eosinophilic (T2) mainly	Neutrophilic/macrophage
Key cytokines	IL-4, IL-5, IL-13	IL-8, TNF-α, IL-17
Reversibility	Yes (≥12% + 200mL)	Incomplete (<12%)
DLCO	Normal	Reduced
CT findings	Normal or hyperinflation	Emphysema, air trapping
Steroid response	Excellent (T2)	Poor (largely resistant)
Mucus plugs	Yes (Curschmann spirals, Charcot-Leyden crystals)	Chronic sputum
Progression	Usually stable	Progressive irreversible
Biologics	Yes (5 targets approved)	Dupilumab for eos COPD only

Sources:

Harrison's Principles of Internal Medicine 22E (2025), Chapter 298 (Asthma)
Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 44 (Pulmonary Pharmacology)
Cellular and Molecular Immunology (Abbas), Chapter 20 (Immediate Hypersensitivity)
Murray & Nadel's Textbook of Respiratory Medicine, Chapters 62, 27 (Asthma Assessment, Sleep)
Fishman's Pulmonary Diseases and Disorders, Chapter on Asthma
GINA 2026 Global Strategy Report (released May 5, 2026)
Systematic Review, PMID 40520782: Umbrella review of biologics for severe asthma (2025)

Create a reference PDF summarizing asthma management algorithms and biologic selection criteria

Reading File

Running Command

ls /home/daytona/workspace/ 2>/dev/null || echo "workspace empty"

Running Command

mkdir -p /home/daytona/workspace/asthma-pdf && python3 -c "from reportlab.lib import colors; print('reportlab ok')" && python3 -c "from reportlab.platypus import SimpleDocTemplate; print('platypus ok')"

Writing File

~/asthma-pdf/generate_asthma_pdf.py

#!/usr/bin/env python3
"""
Asthma Management Reference PDF
Comprehensive clinical reference for respiratory medicine PGT
Covers: GINA 2026 stepwise management, biologic selection, acute severe asthma, severity assessment
"""

from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm, mm
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    HRFlowable, PageBreak, KeepTogether
)
from reportlab.platypus.flowables import BalancedColumns
from reportlab.graphics.shapes import Drawing, Rect, String, Line, Arrow, Polygon
from reportlab.graphics import renderPDF
from reportlab.graphics.charts.barcharts import VerticalBarChart
from reportlab.pdfgen import canvas
import datetime

# ─────────────────────────── COLOUR PALETTE ───────────────────────────
DARK_BLUE    = colors.HexColor('#1A3A5C')
MED_BLUE     = colors.HexColor('#2E6DA4')
LIGHT_BLUE   = colors.HexColor('#D6E8F7')
TEAL         = colors.HexColor('#007B8A')
LIGHT_TEAL   = colors.HexColor('#D0F0F3')
GREEN        = colors.HexColor('#1E7A45')
LIGHT_GREEN  = colors.HexColor('#D4EDDA')
ORANGE       = colors.HexColor('#D4600A')
LIGHT_ORANGE = colors.HexColor('#FDEBD0')
RED          = colors.HexColor('#B22222')
LIGHT_RED    = colors.HexColor('#FADBD8')
YELLOW       = colors.HexColor('#856404')
LIGHT_YELLOW = colors.HexColor('#FFF3CD')
PURPLE       = colors.HexColor('#5B2C8D')
LIGHT_PURPLE = colors.HexColor('#E8D5F5')
GREY_LIGHT   = colors.HexColor('#F5F7FA')
GREY_MED     = colors.HexColor('#DEE2E6')
GREY_DARK    = colors.HexColor('#6C757D')
WHITE        = colors.white
BLACK        = colors.black

# ─────────────────────────── PAGE SETUP ───────────────────────────────
OUTPUT = '/home/daytona/workspace/asthma-pdf/Asthma_Management_Reference.pdf'
PAGE_W, PAGE_H = A4
MARGIN = 1.6 * cm

def make_doc():
    doc = SimpleDocTemplate(
        OUTPUT,
        pagesize=A4,
        leftMargin=MARGIN, rightMargin=MARGIN,
        topMargin=2.2*cm, bottomMargin=2.0*cm,
        title='Asthma Management Reference – GINA 2026',
        author='Orris Medical AI',
        subject='Respiratory Medicine – PGT Reference',
    )
    return doc

# ─────────────────────────── STYLES ───────────────────────────────────
ss = getSampleStyleSheet()

def S(name, parent='Normal', **kw):
    return ParagraphStyle(name, parent=ss[parent], **kw)

COVER_TITLE  = S('CoverTitle', 'Normal',
                 fontSize=28, leading=34, textColor=WHITE,
                 fontName='Helvetica-Bold', alignment=TA_CENTER)
COVER_SUB    = S('CoverSub',   'Normal',
                 fontSize=14, leading=18, textColor=LIGHT_BLUE,
                 fontName='Helvetica', alignment=TA_CENTER)
COVER_NOTE   = S('CoverNote',  'Normal',
                 fontSize=9,  leading=12, textColor=GREY_MED,
                 fontName='Helvetica-Oblique', alignment=TA_CENTER)

H1 = S('H1', 'Normal',
        fontSize=13, leading=16, textColor=WHITE,
        fontName='Helvetica-Bold', alignment=TA_LEFT,
        spaceBefore=4, spaceAfter=2,
        backColor=DARK_BLUE, borderPadding=(5,8,5,8))

H2 = S('H2', 'Normal',
        fontSize=11, leading=14, textColor=DARK_BLUE,
        fontName='Helvetica-Bold',
        spaceBefore=8, spaceAfter=3,
        borderPadding=(0,0,2,0))

H3 = S('H3', 'Normal',
        fontSize=9.5, leading=12, textColor=MED_BLUE,
        fontName='Helvetica-Bold',
        spaceBefore=6, spaceAfter=2)

BODY = S('Body', 'Normal',
         fontSize=8.5, leading=12, textColor=BLACK,
         fontName='Helvetica',
         spaceAfter=3, alignment=TA_JUSTIFY)

BODY_BOLD = S('BodyBold', 'Normal',
              fontSize=8.5, leading=12, textColor=DARK_BLUE,
              fontName='Helvetica-Bold', spaceAfter=2)

BULLET = S('Bullet', 'Normal',
           fontSize=8.5, leading=12, textColor=BLACK,
           fontName='Helvetica',
           leftIndent=14, firstLineIndent=-10,
           spaceAfter=2)

NOTE = S('Note', 'Normal',
         fontSize=7.5, leading=10.5, textColor=GREY_DARK,
         fontName='Helvetica-Oblique',
         leftIndent=4, spaceAfter=2)

WARN = S('Warn', 'Normal',
         fontSize=8, leading=11, textColor=RED,
         fontName='Helvetica-Bold',
         leftIndent=8, spaceAfter=3)

TH = S('TH', 'Normal',
       fontSize=8, leading=10, textColor=WHITE,
       fontName='Helvetica-Bold', alignment=TA_CENTER)

TC = S('TC', 'Normal',
       fontSize=7.8, leading=10.5, textColor=BLACK,
       fontName='Helvetica', alignment=TA_LEFT)

TC_C = S('TC_C', 'Normal',
         fontSize=7.8, leading=10.5, textColor=BLACK,
         fontName='Helvetica', alignment=TA_CENTER)

TC_B = S('TC_B', 'Normal',
         fontSize=7.8, leading=10.5, textColor=DARK_BLUE,
         fontName='Helvetica-Bold', alignment=TA_LEFT)

FOOTER_STYLE = S('Footer', 'Normal',
                 fontSize=7, leading=9, textColor=GREY_DARK,
                 fontName='Helvetica', alignment=TA_CENTER)

# ─────────────────────────── HELPERS ──────────────────────────────────
def HR(color=GREY_MED, width=1, spaceB=4, spaceA=4):
    return HRFlowable(width='100%', thickness=width, color=color,
                      spaceAfter=spaceA, spaceBefore=spaceB)

def SP(h=0.3):
    return Spacer(1, h*cm)

def p(text, style=BODY):
    return Paragraph(text, style)

def bullet(text, symbol='•'):
    return Paragraph(f'{symbol} {text}', BULLET)

def section_header(title, color=DARK_BLUE, text_color=WHITE):
    data = [[Paragraph(title, ParagraphStyle('sh', parent=H1,
                                              backColor=color,
                                              textColor=text_color))]]
    t = Table(data, colWidths=[PAGE_W - 2*MARGIN])
    t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), color),
        ('ROUNDEDCORNERS', [4]),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING', (0,0), (-1,-1), 10),
    ]))
    return t

def info_box(title, content_paras, bg=LIGHT_BLUE, border=MED_BLUE):
    """A titled info box."""
    inner = [[p(title, S('ib_title','Normal',
                          fontSize=8.5, fontName='Helvetica-Bold',
                          textColor=border))]]
    for c in content_paras:
        inner.append([c])
    t = Table(inner, colWidths=[PAGE_W - 2*MARGIN - 0.4*cm])
    t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), bg),
        ('BOX', (0,0), (-1,-1), 1, border),
        ('LEFTPADDING', (0,0), (-1,-1), 8),
        ('RIGHTPADDING', (0,0), (-1,-1), 8),
        ('TOPPADDING', (0,0), (-1,-1), 4),
        ('BOTTOMPADDING', (0,0), (-1,-1), 4),
        ('ROUNDEDCORNERS', [4]),
    ]))
    return t

def make_table(headers, rows, col_widths, header_bg=DARK_BLUE,
               row_alt=GREY_LIGHT, zebra=True):
    header_row = [Paragraph(h, TH) for h in headers]
    data = [header_row]
    for i, row in enumerate(rows):
        data.append([Paragraph(str(c), TC) if not isinstance(c, Paragraph) else c
                     for c in row])
    t = Table(data, colWidths=col_widths, repeatRows=1)
    style = [
        ('BACKGROUND', (0,0), (-1,0), header_bg),
        ('GRID', (0,0), (-1,-1), 0.4, GREY_MED),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [WHITE, row_alt] if zebra else [WHITE]),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 4),
        ('BOTTOMPADDING', (0,0), (-1,-1), 4),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
        ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
    ]
    t.setStyle(TableStyle(style))
    return t

def colored_cell(text, bg, text_color=BLACK, bold=False):
    style = S('cc','Normal', fontSize=7.8, leading=10.5,
               textColor=text_color,
               fontName='Helvetica-Bold' if bold else 'Helvetica',
               alignment=TA_CENTER)
    return Paragraph(text, style)

# ─────────────────────── COVER PAGE ──────────────────────────────────
def build_cover(canvas_obj, doc):
    canvas_obj.saveState()
    # Background gradient-like blocks
    canvas_obj.setFillColor(DARK_BLUE)
    canvas_obj.rect(0, PAGE_H*0.38, PAGE_W, PAGE_H*0.62, fill=1, stroke=0)
    canvas_obj.setFillColor(MED_BLUE)
    canvas_obj.rect(0, PAGE_H*0.35, PAGE_W, PAGE_H*0.05, fill=1, stroke=0)
    canvas_obj.setFillColor(TEAL)
    canvas_obj.rect(0, 0, PAGE_W, PAGE_H*0.35, fill=1, stroke=0)

    # Accent line
    canvas_obj.setStrokeColor(LIGHT_BLUE)
    canvas_obj.setLineWidth(3)
    canvas_obj.line(MARGIN, PAGE_H*0.38, PAGE_W - MARGIN, PAGE_H*0.38)

    # Title
    canvas_obj.setFillColor(WHITE)
    canvas_obj.setFont('Helvetica-Bold', 30)
    canvas_obj.drawCentredString(PAGE_W/2, PAGE_H*0.72, 'ASTHMA MANAGEMENT')
    canvas_obj.setFont('Helvetica-Bold', 24)
    canvas_obj.drawCentredString(PAGE_W/2, PAGE_H*0.65, 'CLINICAL REFERENCE')

    # Subtitle box
    canvas_obj.setFillColor(LIGHT_BLUE)
    canvas_obj.roundRect(MARGIN, PAGE_H*0.58, PAGE_W-2*MARGIN, 1.2*cm, 5, fill=1, stroke=0)
    canvas_obj.setFillColor(DARK_BLUE)
    canvas_obj.setFont('Helvetica-Bold', 12)
    canvas_obj.drawCentredString(PAGE_W/2, PAGE_H*0.587, 'Algorithms, Biologic Selection & Acute Management')

    # Info boxes in lower section
    boxes = [
        ('GINA 2026',        'Stepwise Management\n5-Step Algorithm'),
        ('BIOLOGICS',        'Selection Criteria\n8 Approved Agents'),
        ('ACUTE ASTHMA',     'Severity Grading\nStatus Asthmaticus'),
        ('BIOMARKERS',       'FeNO · Eosinophils\nIgE · Periostin'),
    ]
    bw = (PAGE_W - 2*MARGIN - 0.3*cm*3) / 4
    bx = MARGIN
    by = PAGE_H*0.17
    for i, (title, desc) in enumerate(boxes):
        canvas_obj.setFillColor(colors.HexColor('#1A6B7C'))
        canvas_obj.roundRect(bx, by, bw, 2.8*cm, 5, fill=1, stroke=0)
        canvas_obj.setStrokeColor(LIGHT_TEAL)
        canvas_obj.setLineWidth(1)
        canvas_obj.roundRect(bx, by, bw, 2.8*cm, 5, fill=0, stroke=1)
        canvas_obj.setFillColor(LIGHT_TEAL)
        canvas_obj.setFont('Helvetica-Bold', 9)
        canvas_obj.drawCentredString(bx + bw/2, by + 2.0*cm, title)
        canvas_obj.setFillColor(WHITE)
        canvas_obj.setFont('Helvetica', 7.5)
        lines = desc.split('\n')
        for j, line in enumerate(lines):
            canvas_obj.drawCentredString(bx + bw/2, by + 1.2*cm - j*0.45*cm, line)
        bx += bw + 0.3*cm

    # Footer
    canvas_obj.setFillColor(GREY_LIGHT)
    canvas_obj.setFont('Helvetica-Oblique', 7.5)
    canvas_obj.drawCentredString(PAGE_W/2, 0.9*cm,
        f'Prepared for Respiratory Medicine PGT  |  Based on GINA 2026, Harrison\'s 22E, Fishman\'s Pulmonary  |  {datetime.date.today().strftime("%B %Y")}')
    canvas_obj.restoreState()

# ─────────────────────── PAGE TEMPLATE ───────────────────────────────
def build_page_header_footer(canvas_obj, doc):
    canvas_obj.saveState()
    # Header bar
    canvas_obj.setFillColor(DARK_BLUE)
    canvas_obj.rect(0, PAGE_H - 1.4*cm, PAGE_W, 1.4*cm, fill=1, stroke=0)
    canvas_obj.setFillColor(WHITE)
    canvas_obj.setFont('Helvetica-Bold', 9)
    canvas_obj.drawString(MARGIN, PAGE_H - 0.9*cm, 'ASTHMA MANAGEMENT REFERENCE')
    canvas_obj.setFont('Helvetica', 8)
    canvas_obj.drawRightString(PAGE_W - MARGIN, PAGE_H - 0.9*cm,
        f'GINA 2026  |  Harrison\'s 22E  |  Fishman\'s Pulmonary')
    # Footer
    canvas_obj.setFillColor(GREY_LIGHT)
    canvas_obj.rect(0, 0, PAGE_W, 1.2*cm, fill=1, stroke=0)
    canvas_obj.setStrokeColor(GREY_MED)
    canvas_obj.setLineWidth(0.5)
    canvas_obj.line(0, 1.2*cm, PAGE_W, 1.2*cm)
    canvas_obj.setFillColor(GREY_DARK)
    canvas_obj.setFont('Helvetica', 7)
    canvas_obj.drawCentredString(PAGE_W/2, 0.45*cm,
        f'For educational use only – Not for clinical decision-making without specialist review  |  Page {doc.page}')
    canvas_obj.restoreState()

# ─────────────────────────── CONTENT ──────────────────────────────────
def build_story():
    story = []
    W = PAGE_W - 2*MARGIN  # usable width

    # ══════════════════════════════════════════════════════════════════
    # PAGE 1 – DEFINITION, EPIDEMIOLOGY, DIAGNOSIS OVERVIEW
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.3))
    story.append(section_header('1.  DEFINITION & KEY CONCEPTS'))
    story.append(SP(0.3))

    defn_data = [
        [Paragraph('<b>ASTHMA</b> is a heterogeneous disease characterised by <b>chronic airway inflammation</b>, '
                   '<b>airway hyperresponsiveness (AHR)</b>, and <b>variable airflow obstruction</b> that is '
                   'usually reversible. In a large proportion, inflammation is <i>eosinophilic (T2-high)</i>; '
                   'some patients present with neutrophilic or paucigranulocytic inflammation (T2-low).', BODY)]
    ]
    t = Table(defn_data, colWidths=[W])
    t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), LIGHT_BLUE),
        ('BOX', (0,0), (-1,-1), 1.5, MED_BLUE),
        ('LEFTPADDING', (0,0), (-1,-1), 10),
        ('RIGHTPADDING', (0,0), (-1,-1), 10),
        ('TOPPADDING', (0,0), (-1,-1), 8),
        ('BOTTOMPADDING', (0,0), (-1,-1), 8),
    ]))
    story.append(t)
    story.append(SP(0.4))

    # Three-column key facts
    facts = [
        [Paragraph('<b>GLOBAL BURDEN</b>\n262 million people\nworldwide affected', TC_C),
         Paragraph('<b>US PREVALENCE</b>\n7.9% adults\n8.4% children', TC_C),
         Paragraph('<b>ECONOMICS</b>\nUS $82 billion/year\ntotal burden (2013)', TC_C),
         Paragraph('<b>MORTALITY</b>\n~3–4,000 deaths/year\nin USA; preventable', TC_C)],
    ]
    fact_t = Table(facts, colWidths=[W/4]*4)
    fact_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (0,0), LIGHT_BLUE),
        ('BACKGROUND', (1,0), (1,0), LIGHT_GREEN),
        ('BACKGROUND', (2,0), (2,0), LIGHT_ORANGE),
        ('BACKGROUND', (3,0), (3,0), LIGHT_RED),
        ('BOX', (0,0), (-1,-1), 0.5, GREY_MED),
        ('INNERGRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('ALIGN', (0,0), (-1,-1), 'CENTER'),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 6),
        ('BOTTOMPADDING', (0,0), (-1,-1), 6),
    ]))
    story.append(fact_t)
    story.append(SP(0.5))

    # ── DIAGNOSIS CRITERIA ──
    story.append(p('DIAGNOSTIC CRITERIA', H2))
    story.append(HR(MED_BLUE, 1.5, 2, 5))

    diag_headers = ['Criterion', 'Threshold / Finding', 'Notes']
    diag_rows = [
        [p('<b>Spirometry reversibility</b>', TC_B),
         'FEV₁ ↑ ≥12% AND ≥200 mL post-bronchodilator',
         'Most specific objective test; confirm before starting ICS if possible'],
        [p('<b>PEFR variability</b>', TC_B),
         '>10% diurnal variability (am vs pm)',
         'Higher variability = worse control; better predictor of exacerbations than single PEFR'],
        [p('<b>Methacholine PC₂₀</b>', TC_B),
         '<8 mg/mL = significant AHR',
         'High sensitivity; false positives in COPD, rhinitis, post-viral; use when spirometry normal'],
        [p('<b>Mannitol challenge</b>', TC_B),
         '≥15% fall in FEV₁ at ≤635 mg cumulative',
         'Higher specificity than methacholine for active asthma'],
        [p('<b>FeNO</b>', TC_B),
         '≥40 ppb = high T2 inflammation',
         '<25 ppb = eosinophilic inflammation less likely; falls with ICS (adherence marker)'],
        [p('<b>Trial of ICS therapy</b>', TC_B),
         'Significant symptomatic improvement',
         'In mild cases where spirometry is normal; confirms diagnosis retrospectively'],
    ]
    story.append(make_table(diag_headers, diag_rows,
                            [3.5*cm, 6.5*cm, W-10*cm]))
    story.append(SP(0.3))
    story.append(p('⚠ <b>IMPORTANT:</b> >1/3 of physician-diagnosed asthma does NOT meet objective criteria. '
                   'Always confirm with spirometry or provocation testing before starting long-term therapy.', WARN))
    story.append(SP(0.5))

    # ── BIOMARKERS TABLE ──
    story.append(p('KEY BIOMARKERS & INTERPRETATION', H2))
    story.append(HR(MED_BLUE, 1.5, 2, 5))

    bio_headers = ['Biomarker', 'Low', 'Borderline', 'High', 'Clinical Use']
    bio_rows = [
        ['FeNO (ppb)',
         colored_cell('<25\nT2-low', LIGHT_GREEN, GREEN, True),
         colored_cell('25–39\nBorderline', LIGHT_YELLOW, YELLOW, True),
         colored_cell('≥40\nEosinophilic', LIGHT_RED, RED, True),
         'T2 phenotyping; ICS response prediction; adherence monitoring; biologic eligibility'],
        ['Blood Eos (/µL)',
         colored_cell('<150\nT2-low', LIGHT_GREEN, GREEN, True),
         colored_cell('150–299\nMild T2', LIGHT_YELLOW, YELLOW, True),
         colored_cell('≥300\nHigh T2', LIGHT_RED, RED, True),
         'Biologic eligibility (mepolizumab ≥150/300, benralizumab ≥300, reslizumab ≥400)'],
        ['Total IgE (IU/mL)',
         colored_cell('<30\nUnlikely allergic', LIGHT_GREEN, GREEN, True),
         colored_cell('30–700\nAllergic range', LIGHT_YELLOW, YELLOW, True),
         colored_cell('>700\nHigh IgE', LIGHT_RED, RED, True),
         'Omalizumab eligibility (IgE 30–700 + perennial allergen sensitisation)'],
        ['Sputum Eos (%)',
         colored_cell('<2%\nNormal', LIGHT_GREEN, GREEN, True),
         colored_cell('2–3%\nMild eos', LIGHT_YELLOW, YELLOW, True),
         colored_cell('≥3%\nEosinophilic', LIGHT_RED, RED, True),
         'Gold standard for T2 phenotyping; ICS dose titration in severe asthma'],
        ['Periostin (ng/mL)',
         colored_cell('<25\nLow', LIGHT_GREEN, GREEN, True),
         colored_cell('25–50\nModerate', LIGHT_YELLOW, YELLOW, True),
         colored_cell('>50\nHigh (esp. AERD)', LIGHT_RED, RED, True),
         'T2 inflammation marker; highest in AERD (mean 64.7); predicts dupilumab response'],
    ]
    t = make_table(bio_headers, bio_rows,
                   [2.8*cm, 2.2*cm, 2.2*cm, 2.2*cm, W-9.4*cm])
    story.append(t)

    story.append(PageBreak())

    # ══════════════════════════════════════════════════════════════════
    # PAGE 2 – GINA 2026 STEPWISE MANAGEMENT
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.2))
    story.append(section_header('2.  GINA 2026 STEPWISE MANAGEMENT ALGORITHM', TEAL))
    story.append(SP(0.3))

    # Key paradigm box
    story.append(info_box(
        '🔑  KEY PARADIGM CHANGE – GINA 2026 (Anti-Inflammatory Reliever, AIR)',
        [
            p('<b>ICS/formoterol as reliever at ALL steps</b> – replacing SABA-only approach. '
              'Using ICS/formoterol as-needed ensures anti-inflammatory therapy accompanies '
              'every bronchodilator dose, reducing severe exacerbations and OCS use.', BODY),
            p('<b>ICS-formoterol (MART strategy)</b> = Maintenance And Reliever Therapy: '
              'same inhaler used for both daily controller AND as-needed relief at steps 3–4.', BODY),
            p('<b>Never use LABA as monotherapy</b> in asthma. LABAs must always be combined with ICS.', WARN),
        ], LIGHT_TEAL, TEAL))
    story.append(SP(0.4))

    # 5-Step Table
    step_colors = [LIGHT_GREEN, LIGHT_BLUE, LIGHT_YELLOW, LIGHT_ORANGE, LIGHT_RED]
    step_borders = [GREEN, MED_BLUE, YELLOW, ORANGE, RED]
    step_labels = ['STEP 1', 'STEP 2', 'STEP 3', 'STEP 4', 'STEP 5']
    step_severity = ['Intermittent\n(<2×/month)', 'Mild persistent\n(≥2×/month,\nnot daily)',
                     'Moderate\n(daily symptoms)', 'Severe\n(uncontrolled\non step 3)',
                     'Very severe\n(uncontrolled\non step 4)']
    step_controller = [
        'As-needed\nlow-dose\nICS-formoterol*',
        'Low-dose ICS daily\n+ as-needed\nICS-formoterol*',
        'Low-dose\nICS/LABA\n(daily)',
        'Medium-dose\nICS/LABA\n(daily)',
        'High-dose ICS/LABA\n+ phenotypic\nassessment\n± biologic therapy',
    ]
    step_reliever = ['ICS/formoterol\n(AIR)'] * 5
    step_alt = [
        'Low-dose ICS\nwith each SABA†',
        'LTRA (note:\nmontelukast\nwarning!)',
        'Medium-dose ICS\nor low-dose\nICS + LTRA',
        'Add LAMA\n(tiotropium)\nor add LTRA',
        'Low-dose OCS\n(last resort;\nconsider side-effects)',
    ]

    step_data = [
        [Paragraph('<b>STEP</b>', TH),
         Paragraph('<b>SEVERITY</b>', TH),
         Paragraph('<b>PREFERRED\nCONTROLLER</b>', TH),
         Paragraph('<b>PREFERRED\nRELIEVER</b>', TH),
         Paragraph('<b>ALTERNATIVE /\nADD-ON OPTIONS</b>', TH)],
    ]
    for i in range(5):
        step_data.append([
            colored_cell(step_labels[i], step_colors[i],
                         step_borders[i], True),
            Paragraph(step_severity[i], TC_C),
            Paragraph(step_controller[i], TC_C),
            Paragraph(step_reliever[i], TC_C),
            Paragraph(step_alt[i], TC),
        ])

    step_t = Table(step_data, colWidths=[1.6*cm, 2.8*cm, 3.6*cm, 2.6*cm, W-10.6*cm],
                   repeatRows=1)
    step_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), DARK_BLUE),
        ('TEXTCOLOR', (0,0), (-1,0), WHITE),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('ALIGN', (0,0), (-1,-1), 'CENTER'),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('ROWBACKGROUNDS', (0,1), (-1,-1),
         [LIGHT_GREEN, LIGHT_BLUE, LIGHT_YELLOW, LIGHT_ORANGE, LIGHT_RED]),
    ]))
    story.append(step_t)
    story.append(SP(0.25))

    # Footnotes
    story.append(p('* As-needed ICS-formoterol = Anti-Inflammatory Reliever (AIR); preferred at all steps per GINA 2026.  '
                   '† NAEPP alternative: ICS taken whenever SABA taken (step 1). '
                   '‡ ICS/formoterol MART = same inhaler for controller + reliever (steps 3–4).', NOTE))
    story.append(SP(0.4))

    # Stepping up/down rules
    story.append(p('STEPPING UP / DOWN RULES', H2))
    story.append(HR(TEAL, 1.5, 2, 5))

    updown_data = [
        [Paragraph('<b>Before Stepping UP – Check First:</b>', TC_B),
         Paragraph('<b>Stepping DOWN – When to:</b>', TC_B)],
        [Paragraph('✓ Inhaler technique correct?\n'
                   '✓ Adherence adequate (>80%)?\n'
                   '✓ Trigger avoidance addressed?\n'
                   '✓ Comorbidities treated (GERD, rhinitis, OSA, VCD)?\n'
                   '✓ Diagnosis confirmed (not VCD/HF mimicking asthma)?\n\n'
                   'Step up only if poor control persists ≥2–3 months\n'
                   'after all of the above are optimised.', BODY),
         Paragraph('✓ Asthma well-controlled for ≥3 months\n'
                   '✓ No exacerbations, normal FEV₁\n'
                   '✓ Not high-risk season (e.g., viral season)\n\n'
                   '⚠ NEVER fully stop ICS (even in step 1)\n'
                   '⚠ ICS dose reductions: decrease by 25–50% every 3 months\n'
                   '⚠ ICS discontinuation risks exacerbation and rebound eosinophilia', BODY)],
    ]
    updown_t = Table(updown_data, colWidths=[W/2, W/2])
    updown_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), LIGHT_TEAL),
        ('BACKGROUND', (0,1), (0,1), LIGHT_GREEN),
        ('BACKGROUND', (1,1), (1,1), LIGHT_YELLOW),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('VALIGN', (0,0), (-1,-1), 'TOP'),
        ('TOPPADDING', (0,0), (-1,-1), 6),
        ('BOTTOMPADDING', (0,0), (-1,-1), 6),
        ('LEFTPADDING', (0,0), (-1,-1), 8),
        ('RIGHTPADDING', (0,0), (-1,-1), 8),
    ]))
    story.append(updown_t)
    story.append(SP(0.4))

    # OCS minimisation (GINA 2026 new)
    story.append(info_box(
        'OCS MINIMISATION – GINA 2026 New Recommendation',
        [
            bullet('All patients must receive <b>ICS-containing therapy</b> – this is non-negotiable.'),
            bullet('ICS-formoterol AIR or ICS-SABA reduces risk of severe exacerbations requiring OCS.'),
            bullet('Optimise modifiable risk factors before adding OCS (see comorbidities).'),
            bullet('If OCS required long-term → refer for phenotyping + biologic therapy assessment.'),
            p('OCS side effects: Diabetes, osteoporosis, HPA axis suppression, cataracts, '
              'weight gain, immunosuppression, hypertension, avascular necrosis.', NOTE),
        ], LIGHT_YELLOW, ORANGE))

    story.append(PageBreak())

    # ══════════════════════════════════════════════════════════════════
    # PAGE 3 – BIOLOGIC SELECTION
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.2))
    story.append(section_header('3.  BIOLOGIC THERAPY – TARGETS, ELIGIBILITY & SELECTION', PURPLE))
    story.append(SP(0.3))

    story.append(p('Biologics are used at <b>Step 5</b> (or after Step 4 failure). All current approved biologics '
                   'target the <b>T2 inflammatory cascade</b>. Selection is based on biomarker profile, '
                   'comorbidities, route/frequency preference, and cost.', BODY))
    story.append(SP(0.3))

    # T2 cascade summary
    cascade_data = [
        [Paragraph('<b>Epithelial Alarmins</b>\n(upstream)', TC_C),
         Paragraph('→', TC_C),
         Paragraph('<b>ILC2 / Th2</b>\nActivation', TC_C),
         Paragraph('→', TC_C),
         Paragraph('<b>IL-4, IL-5, IL-13</b>\n(effector cytokines)', TC_C),
         Paragraph('→', TC_C),
         Paragraph('<b>IgE · Eosinophils\nMucus · AHR · Fibrosis</b>', TC_C)],
        [Paragraph('TSLP, IL-33, IL-25', NOTE),
         Paragraph('', TC_C),
         Paragraph('', TC_C),
         Paragraph('', TC_C),
         Paragraph('IL-4 → IgE switching\nIL-5 → Eosinophil Δ\nIL-13 → Mucus, AHR', NOTE),
         Paragraph('', TC_C),
         Paragraph('', TC_C)],
    ]
    cascade_t = Table(cascade_data, colWidths=[2.8*cm,0.6*cm,2.4*cm,0.6*cm,3.2*cm,0.6*cm,W-10.2*cm])
    cascade_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (0,-1), LIGHT_PURPLE),
        ('BACKGROUND', (2,0), (2,-1), LIGHT_TEAL),
        ('BACKGROUND', (4,0), (4,-1), LIGHT_BLUE),
        ('BACKGROUND', (6,0), (6,-1), LIGHT_RED),
        ('BOX', (0,0), (0,-1), 0.5, PURPLE),
        ('BOX', (2,0), (2,-1), 0.5, TEAL),
        ('BOX', (4,0), (4,-1), 0.5, MED_BLUE),
        ('BOX', (6,0), (6,-1), 0.5, RED),
        ('ALIGN', (0,0), (-1,-1), 'CENTER'),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 4),
        ('BOTTOMPADDING', (0,0), (-1,-1), 4),
    ]))
    story.append(cascade_t)
    story.append(SP(0.4))

    # Biologic table
    story.append(p('APPROVED BIOLOGICS – COMPREHENSIVE COMPARISON', H2))
    story.append(HR(PURPLE, 1.5, 2, 5))

    bio_t_headers = ['Agent', 'Target', 'Route /\nFreq.', 'Eos\nThreshold', 'IgE\nRange',
                     'Key Indications / Notes']
    bio_t_rows = [
        [p('<b>Omalizumab</b>\n(Xolair)', TC_B),
         'Anti-IgE', 'SC\nq2–4w',
         p('Not required\n(IgE-based)', TC_C),
         p('30–700\nIU/mL', TC_C),
         'Perennial allergen sensitisation + IgE 30–700; also: CRSwNP, chronic urticaria; reduces exacerb. 25–50%'],
        [p('<b>Omalizumab-igec</b>\n(biosimilar) ★NEW 2026', TC_B),
         'Anti-IgE', 'SC\nq2–4w',
         p('Not required', TC_C),
         p('30–700\nIU/mL', TC_C),
         'Biosimilar of omalizumab; GINA 2026: now approved for CRSwNP'],
        [p('<b>Mepolizumab</b>\n(Nucala)', TC_B),
         'Anti-IL-5', 'SC 100mg\nq4w',
         p('≥150 screen\n≥300 preferred', TC_C),
         p('N/A', TC_C),
         'Also: EGPA, HES, CRSwNP; reduces exacerb. ~50%; reduces OCS use; weight-independent dose'],
        [p('<b>Reslizumab</b>\n(Cinqair)', TC_B),
         'Anti-IL-5', 'IV 3mg/kg\nq4w',
         p('≥400/µL', TC_C),
         p('N/A', TC_C),
         'Only IV biologic for asthma; weight-based dosing; reduces exacerb. ~50%; anaphylaxis risk (0.3%)'],
        [p('<b>Benralizumab</b>\n(Fasenra)', TC_B),
         'Anti-IL-5Rα', 'SC 30mg\nq4w ×3\nthen q8w',
         p('≥300/µL', TC_C),
         p('N/A', TC_C),
         'Near-complete eosinophil depletion via ADCC; also CRSwNP; convenient q8w maintenance'],
        [p('<b>Depemokimab</b>\n(Slynd) ★GINA 2026', TC_B),
         'Anti-IL-5\n(long-acting)', 'SC\nq6 months',
         p('≥300/µL', TC_C),
         p('N/A', TC_C),
         '★ NEWEST biologic (GINA 2026); longest dosing interval; ≥12y severe eos asthma; ≥18y CRSwNP'],
        [p('<b>Dupilumab</b>\n(Dupixent)', TC_B),
         'Anti-IL-4Rα\n(blocks IL-4\n+ IL-13)', 'SC\nq2w',
         p('≥150/µL or\nFeNO ≥25ppb', TC_C),
         p('N/A', TC_C),
         'Broadest T2 coverage; also: atopic dermatitis, CRSwNP, eosinophilic oesophagitis, COPD with eos; arthralgia SE'],
        [p('<b>Tezepelumab</b>\n(Tezspire)', TC_B),
         'Anti-TSLP\n(upstream\nalarmin)', 'SC 210mg\nq4w',
         p('NONE\nrequired', TC_C),
         p('N/A', TC_C),
         'Broadest efficacy including T2-low/paucigranulocytic; works even with low eos/FeNO; also CRSwNP'],
    ]
    story.append(make_table(bio_t_headers, bio_t_rows,
                            [2.5*cm, 2.0*cm, 1.8*cm, 1.8*cm, 1.5*cm, W-9.6*cm],
                            header_bg=PURPLE))
    story.append(SP(0.3))
    story.append(p('ADCC = Antibody-Dependent Cell-mediated Cytotoxicity. EGPA = Eosinophilic Granulomatosis with Polyangiitis. '
                   'HES = Hypereosinophilic Syndrome. CRSwNP = Chronic Rhinosinusitis with Nasal Polyps. '
                   '★ = new/updated in GINA 2026.', NOTE))
    story.append(SP(0.4))

    # Biologic selection algorithm
    story.append(p('BIOLOGIC SELECTION ALGORITHM (GINA 2026)', H2))
    story.append(HR(PURPLE, 1.5, 2, 5))

    algo_data = [
        [Paragraph('<b>Step 5 Severe Asthma – Assess T2 Biomarkers</b>', TH),
         Paragraph('<b>Biologic of Choice</b>', TH),
         Paragraph('<b>Key Consideration</b>', TH)],
        [Paragraph('<b>Allergic</b>: IgE 30–700 IU/mL + perennial\nallergen sensitisation (any eos level)', TC_B),
         colored_cell('OMALIZUMAB\nor biosimilar', LIGHT_PURPLE, PURPLE, True),
         'Skin prick test / RAST positive; also consider if CRSwNP present'],
        [Paragraph('<b>Eosinophilic</b>: Blood eos ≥300/µL\n(no allergic features / IgE not eligible)', TC_B),
         colored_cell('MEPOLIZUMAB\nBENRALIZUMAB\nDEPEMABOKIMAB★', LIGHT_RED, RED, True),
         'Depemokimab preferred if 6-monthly dosing desired; benralizumab for q8w maintenance'],
        [Paragraph('<b>High eosinophils</b>: Blood eos ≥400/µL\n(overweight/obese patient)', TC_B),
         colored_cell('RESLIZUMAB\n(IV, weight-based)', LIGHT_ORANGE, ORANGE, True),
         'Weight-based dosing may be advantageous in obese patients'],
        [Paragraph('<b>T2 + Atopic dermatitis, CRSwNP, or\neosinophilic oesophagitis comorbidity</b>', TC_B),
         colored_cell('DUPILUMAB\n(IL-4Rα)', LIGHT_BLUE, MED_BLUE, True),
         '"One airway, one disease" – addresses multiple atopic manifestations simultaneously'],
        [Paragraph('<b>Uncertain T2 phenotype</b>: Low eos, low FeNO;\nor T2-low / paucigranulocytic', TC_B),
         colored_cell('TEZEPELUMAB\n(anti-TSLP)', LIGHT_TEAL, TEAL, True),
         'Only biologic with no minimum biomarker threshold; broadest efficacy spectrum'],
        [Paragraph('<b>Multiple positive biomarkers</b>: Elevated eos\nAND elevated IgE AND high FeNO', TC_B),
         colored_cell('SELECT BASED ON:\nComorbidities / Cost\nRoute / Frequency', LIGHT_GREEN, GREEN, True),
         'No head-to-head RCTs; GINA 2026 decision tree uses comorbidities + patient preference'],
    ]
    algo_t = Table(algo_data, colWidths=[5.5*cm, 3.8*cm, W-9.3*cm], repeatRows=1)
    algo_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), PURPLE),
        ('TEXTCOLOR', (0,0), (-1,0), WHITE),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [WHITE, GREY_LIGHT]),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
    ]))
    story.append(algo_t)

    story.append(PageBreak())

    # ══════════════════════════════════════════════════════════════════
    # PAGE 4 – ACUTE SEVERE ASTHMA / STATUS ASTHMATICUS
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.2))
    story.append(section_header('4.  ACUTE SEVERE ASTHMA & STATUS ASTHMATICUS', RED))
    story.append(SP(0.3))

    # ABG evolution
    story.append(p('ABG EVOLUTION IN ACUTE ASTHMA ATTACK', H2))
    story.append(HR(RED, 1.5, 2, 5))

    abg_data = [
        [Paragraph('<b>Stage</b>', TH),
         Paragraph('<b>PaO₂</b>', TH),
         Paragraph('<b>PaCO₂</b>', TH),
         Paragraph('<b>pH</b>', TH),
         Paragraph('<b>SpO₂</b>', TH),
         Paragraph('<b>Interpretation / Action</b>', TH)],
        [colored_cell('EARLY\nMILD', LIGHT_GREEN, GREEN, True),
         colored_cell('Normal\nor ↓ mildly', LIGHT_GREEN, GREEN),
         colored_cell('↓ <40\nHypocapnia', LIGHT_GREEN, GREEN, True),
         colored_cell('↑ >7.45\nAlkalosis', LIGHT_GREEN, GREEN),
         colored_cell('>95%', LIGHT_GREEN, GREEN),
         'Tachypnoea compensates; hyperventilation. Treat with SABA + ICS.'],
        [colored_cell('MODERATE', LIGHT_YELLOW, YELLOW, True),
         colored_cell('↓ 60–80', LIGHT_YELLOW, YELLOW),
         colored_cell('Normal\n~35–45\n⚠ DANGER', LIGHT_RED, RED, True),
         colored_cell('Normal\n7.40–7.45', LIGHT_YELLOW, YELLOW),
         colored_cell('90–95%', LIGHT_YELLOW, YELLOW),
         '⚠ NORMAL PaCO₂ in DISTRESSED asthmatic = impending respiratory failure. Aggressive treatment.'],
        [colored_cell('SEVERE /\nFAILURE', LIGHT_RED, RED, True),
         colored_cell('↓↓ <60', LIGHT_RED, RED),
         colored_cell('↑ >45\nHypercapnia', LIGHT_RED, RED, True),
         colored_cell('↓ <7.35\nAcidosis', LIGHT_RED, RED, True),
         colored_cell('<90%', LIGHT_RED, RED),
         '⚠ INTUBATE. Permissive hypercapnia strategy. Aim pH ≥7.2; bicarbonate if needed.'],
    ]
    abg_t = Table(abg_data, colWidths=[1.8*cm, 1.8*cm, 2.5*cm, 2.2*cm, 1.8*cm, W-10.1*cm],
                  repeatRows=1)
    abg_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), RED),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('ALIGN', (0,0), (-1,0), 'CENTER'),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
    ]))
    story.append(abg_t)
    story.append(SP(0.3))

    # Severity grading
    story.append(p('SEVERITY GRADING', H2))
    story.append(HR(RED, 1.5, 2, 5))

    sev_headers = ['Feature', 'Mild-Moderate', 'Severe', 'Life-Threatening']
    sev_rows = [
        ['Speech', 'Full sentences', 'Phrases', 'Words / unable to speak'],
        ['RR (breaths/min)', '20–25', '25–30', '>30'],
        ['HR (bpm)', '<110', '110–120', '>120'],
        ['PEFR (% best/predicted)', '>50–75%', '33–50%', '<33% ("brittle")'],
        ['SpO₂', '>95%', '92–95%', '<92%'],
        ['Wheeze', 'Moderate', 'Loud', '★ SILENT CHEST (DANGER)'],
        ['Mental status', 'Normal', 'Agitated', '★ Drowsy / confused'],
        ['PaCO₂', '<40 (hypocapnia)', '<40', '★ ≥45 (fatigue/failure)'],
    ]
    sev_col = [4.0*cm, 3.5*cm, 3.0*cm, W-10.5*cm]
    data = [[Paragraph(h, TH) for h in sev_headers]] + \
           [[Paragraph(str(r[i]), TC) for i in range(4)] for r in sev_rows]
    # Highlight danger signs in last column
    for i, r in enumerate(sev_rows):
        if '★' in r[3]:
            data[i+1][3] = Paragraph(r[3].replace('★',''), WARN)
    sev_t = Table(data, colWidths=sev_col, repeatRows=1)
    sev_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), RED),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [WHITE, GREY_LIGHT]),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 4),
        ('BOTTOMPADDING', (0,0), (-1,-1), 4),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
        # Highlight life-threatening column
        ('BACKGROUND', (3,1), (3,-1), colors.HexColor('#FFF5F5')),
        ('TEXTCOLOR', (3,1), (3,-1), RED),
    ]))
    story.append(sev_t)
    story.append(SP(0.3))

    # Management protocol
    story.append(p('ACUTE MANAGEMENT PROTOCOL (GINA 2026)', H2))
    story.append(HR(RED, 1.5, 2, 5))

    mgmt_data = [
        [Paragraph('<b>TIME</b>', TH),
         Paragraph('<b>INTERVENTION</b>', TH),
         Paragraph('<b>DOSE / DETAILS</b>', TH)],
        [colored_cell('0–20 min\nIMM-\nEDIATE', LIGHT_RED, RED, True),
         Paragraph('1. Supplemental O₂\n2. SABA (salbutamol)\n3. Ipratropium bromide\n4. Systemic corticosteroids', TC_B),
         Paragraph('SpO₂ target 93–95% (avoid hyperoxia, GINA 2026)\n'
                   'MDI+spacer: 4–8 puffs; or nebuliser 2.5–5mg; repeat ×3 q20min\n'
                   '4–8 puffs MDI or 0.5mg neb; with each salbutamol dose (up to ×3)\n'
                   'Prednisolone 40–50mg PO or Hydrocortisone 100–200mg IV', TC)],
        [colored_cell('1–2 h\nNO RESP-\nONSE', LIGHT_ORANGE, ORANGE, True),
         Paragraph('5. IV Magnesium sulfate\n6. IV salbutamol infusion\n7. IV aminophylline\n8. Measure PEFR/FEV₁', TC_B),
         Paragraph('2g IV over 20 min (single dose); reduces hospitalisation + intubation\n'
                   '5–15 mcg/kg/min; continuous; if not responding to inhaled\n'
                   'Loading 5mg/kg over 20min (if not on oral theophylline); rarely used\n'
                   'PEFR >60% → likely discharge with step-up; <60% → admit', TC)],
        [colored_cell('If\nFAILING', LIGHT_RED, RED, True),
         Paragraph('9. NIV (BiPAP)\n10. Heliox\n11. INTUBATION', TC_B),
         Paragraph('BiPAP well-tolerated; reduces intubation rate; avoids ICU in selected patients\n'
                   '60:40 He:O₂; reduces turbulence; decreases WOB; use while preparing for intubation\n'
                   'RSI with KETAMINE (preferred: bronchodilator properties); avoid propofol if hypotensive', TC)],
        [colored_cell('MV\nSTRATEGY', GREY_DARK, WHITE, True),
         Paragraph('Mechanical ventilation\nin status asthmaticus', TC_B),
         Paragraph('Low RR (8–12/min); low TV (6–8 mL/kg IBW); long expiratory time (I:E 1:3 or 1:4)\n'
                   'Permissive hypercapnia: allow PaCO₂ to rise; target pH ≥7.2; NaHCO₃ if pH <7.2\n'
                   'Monitor auto-PEEP (dynamic hyperinflation); consider NMB short-term\n'
                   'Volatile anaesthetics (isoflurane/sevoflurane) for refractory bronchospasm', TC)],
    ]
    mgmt_t = Table(mgmt_data, colWidths=[2.2*cm, 4.8*cm, W-7.0*cm], repeatRows=1)
    mgmt_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), RED),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING', (0,0), (-1,-1), 5),
        ('RIGHTPADDING', (0,0), (-1,-1), 5),
    ]))
    story.append(mgmt_t)
    story.append(SP(0.3))

    # ATS/IDSA severe criteria
    story.append(info_box(
        'ATS/IDSA CRITERIA FOR SEVERE / ICU ASTHMA',
        [
            p('<b>Major criteria (1 = ICU):</b> Invasive mechanical ventilation; '
              'haemodynamic compromise requiring vasopressor support', BODY),
            p('<b>Minor criteria (≥3 = ICU):</b> RR ≥30; PaO₂/FiO₂ ≤250; multilobar infiltrates; '
              'confusion/disorientation; uremia (BUN ≥20 mg/dL); WBC <4000 cells/mm³; '
              'platelets <100,000; hypothermia (<36°C); hypotension requiring aggressive fluid resuscitation', BODY),
        ], LIGHT_RED, RED))

    story.append(PageBreak())

    # ══════════════════════════════════════════════════════════════════
    # PAGE 5 – ASTHMA MORTALITY RISK & SPECIAL SITUATIONS
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.2))
    story.append(section_header('5.  MORTALITY RISK FACTORS & SPECIAL CLINICAL SCENARIOS', ORANGE))
    story.append(SP(0.3))

    # Mortality risk factors
    story.append(p('FATALITY RISK INDICATORS (GINA 2026 – NEW EMPHASIS)', H2))
    story.append(HR(ORANGE, 1.5, 2, 5))

    risk_col1 = [
        '<b>1.</b> Previous near-fatal attack (intubation / ICU)',
        '<b>2.</b> Hospitalisation for asthma in past 12 months',
        '<b>3.</b> ≥2 ED visits in past 6 months',
        '<b>4.</b> ≥2 courses of systemic corticosteroids in past year',
        '<b>5.</b> Overuse of SABAs (>1 canister/month)',
        '<b>6.</b> Currently not using ICS or non-adherent to ICS',
    ]
    risk_col2 = [
        '<b>7.</b> No written asthma action plan',
        '<b>8.</b> Illicit drug use',
        '<b>9.</b> Depression or anxiety',
        '<b>10.</b> Severe psychosocial problems',
        '<b>11.</b> Lower socioeconomic status / limited healthcare access',
        '<b>12.</b> Food allergy + confirmed asthma (anaphylaxis risk)',
    ]
    risk_data = [
        [Paragraph('<b>⚠  HIGH-RISK PATIENT INDICATORS</b>', TH),
         Paragraph('<b>⚠  FURTHER RISK FACTORS</b>', TH)],
    ]
    for i in range(6):
        risk_data.append([
            Paragraph(risk_col1[i], BODY),
            Paragraph(risk_col2[i], BODY),
        ])
    risk_t = Table(risk_data, colWidths=[W/2, W/2])
    risk_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), ORANGE),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [LIGHT_ORANGE, WHITE]),
        ('GRID', (0,0), (-1,-1), 0.5, GREY_MED),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
        ('LEFTPADDING', (0,0), (-1,-1), 8),
        ('RIGHTPADDING', (0,0), (-1,-1), 8),
    ]))
    story.append(risk_t)
    story.append(SP(0.4))

    # Special scenarios
    story.append(p('SPECIAL CLINICAL SCENARIOS', H2))
    story.append(HR(ORANGE, 1.5, 2, 5))

    # Two-column layout for special scenarios
    col_w = (W - 0.4*cm) / 2

    # AERD
    aerd_data = [
        [Paragraph('<b>ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)</b>', TC_B)],
        [Paragraph('<b>Triad:</b> Asthma + Nasal polyposis + NSAID/aspirin sensitivity\n'
                   '<b>Mechanism:</b> COX-1 inhibition → ↓PGE₂ + ↑CysLTs → bronchoconstriction\n'
                   '<b>Diagnosis:</b> Aspirin oral/inhalation challenge (gold standard)\n'
                   '<b>Tx:</b> Avoid COX-1 inhibitors; LTRAs; aspirin desensitisation; dupilumab/tezepelumab for nasal polyps\n'
                   '<b>Periostin:</b> Highest among asthma endotypes (mean 64.7 ng/mL)', BODY)],
    ]
    aerd_t = Table(aerd_data, colWidths=[col_w])
    aerd_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), LIGHT_ORANGE),
        ('BOX', (0,0), (-1,-1), 1, ORANGE),
        ('LEFTPADDING', (0,0), (-1,-1), 7),
        ('RIGHTPADDING', (0,0), (-1,-1), 7),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ]))

    # ACO
    aco_data = [
        [Paragraph('<b>ASTHMA-COPD OVERLAP (ACO)</b>', TC_B)],
        [Paragraph('<b>Features:</b> Variable symptoms (asthma) + incomplete reversibility + smoking history (COPD)\n'
                   '<b>Spirometry:</b> Partial reversibility; FEV₁/FVC <0.70 post-BD\n'
                   '<b>Key rule:</b> ICS is MANDATORY (reduces mortality vs withdrawal)\n'
                   '<b>Add-on:</b> LABA + LAMA both may be used\n'
                   '⚠ SABA monotherapy is CONTRAINDICATED in ACO', BODY)],
    ]
    aco_t = Table(aco_data, colWidths=[col_w])
    aco_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), LIGHT_TEAL),
        ('BOX', (0,0), (-1,-1), 1, TEAL),
        ('LEFTPADDING', (0,0), (-1,-1), 7),
        ('RIGHTPADDING', (0,0), (-1,-1), 7),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ]))

    # Pregnancy
    preg_data = [
        [Paragraph('<b>ASTHMA IN PREGNANCY</b>', TC_B)],
        [Paragraph('<b>~4%</b> of pregnant women have asthma; 1/3 worsen during pregnancy\n'
                   '<b>Risk:</b> Moderate-severe asthma → preterm labour, LBW, perinatal death, pre-eclampsia\n'
                   '<b>ABG normal:</b> pH 7.45, PaCO₂ 27–32 mmHg → "normal" PaCO₂ 40 = hypercapnia!\n'
                   '<b>FEV₁ and PEFR:</b> Unchanged in pregnancy – useful for monitoring\n'
                   '<b>Safety:</b> ICS (all safe); salbutamol safe; montelukast avoid if possible', BODY)],
    ]
    preg_t = Table(preg_data, colWidths=[col_w])
    preg_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), LIGHT_PURPLE),
        ('BOX', (0,0), (-1,-1), 1, PURPLE),
        ('LEFTPADDING', (0,0), (-1,-1), 7),
        ('RIGHTPADDING', (0,0), (-1,-1), 7),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ]))

    # EIB
    eib_data = [
        [Paragraph('<b>EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB)</b>', TC_B)],
        [Paragraph('<b>Mechanism:</b> Hyperventilation → airway desiccation → osmolarity change → mediator release\n'
                   '<b>Peak:</b> 5–15 min post-exercise; resolves 30–60 min spontaneously\n'
                   '<b>Diagnosis:</b> >10–15% fall in FEV₁ at 15–30 min post-exercise challenge\n'
                   '<b>Refractory period:</b> 2h window after exercise → less bronchoconstriction (mast cell depletion)\n'
                   '<b>Rx:</b> Pre-treatment SABA 15–20 min before; warm-up; ICS long-term', BODY)],
    ]
    eib_t = Table(eib_data, colWidths=[col_w])
    eib_t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), LIGHT_GREEN),
        ('BOX', (0,0), (-1,-1), 1, GREEN),
        ('LEFTPADDING', (0,0), (-1,-1), 7),
        ('RIGHTPADDING', (0,0), (-1,-1), 7),
        ('TOPPADDING', (0,0), (-1,-1), 5),
        ('BOTTOMPADDING', (0,0), (-1,-1), 5),
    ]))

    # Layout in 2 columns
    two_col = Table(
        [[aerd_t, aco_t],
         [SP(0.25), SP(0.25)],
         [preg_t, eib_t]],
        colWidths=[col_w, col_w]
    )
    two_col.setStyle(TableStyle([
        ('LEFTPADDING', (0,0), (-1,-1), 0),
        ('RIGHTPADDING', (0,0), (-1,-1), 0),
        ('TOPPADDING', (0,0), (-1,-1), 0),
        ('BOTTOMPADDING', (0,0), (-1,-1), 0),
        ('INNERGRID', (0,0), (-1,-1), 0, WHITE),
        ('BOX', (0,0), (-1,-1), 0, WHITE),
        ('COLPADDING', (0,0), (-1,-1), 5),
    ]))
    story.append(two_col)
    story.append(SP(0.4))

    # ── COMORBIDITIES TABLE ──
    story.append(p('KEY COMORBIDITIES AFFECTING ASTHMA CONTROL', H2))
    story.append(HR(ORANGE, 1.5, 2, 5))

    comor_headers = ['Comorbidity', 'Impact on Asthma', 'Management']
    comor_rows = [
        ['Rhinosinusitis / Nasal polyps',
         'Worsens AHR via inflammatory mediators, post-nasal drip, neural reflexes',
         'Intranasal steroids (reduce AHR + ED visits); biologics for polyps (dupilumab, tezepelumab)'],
        ['GERD',
         'Independent predictor of exacerbations; microaspiration + vagal reflexes',
         'Treat symptomatic GERD (PPI ± lifestyle); asymptomatic GERD treatment NOT beneficial'],
        ['Obesity',
         '2–4× hospitalisation risk; non-eosinophilic pattern; mechanical restriction + adipokines',
         'Weight loss (bariatric surgery reduces exacerbations); non-T2 management; LAMA add-on'],
        ['OSA',
         'Increased exacerbation severity; AHI correlates with exacerbations; OCS worsens OSA',
         'CPAP → improves QoL, reduces exacerbations, reduces bronchodilator use'],
        ['Anxiety / Depression',
         'Increased exacerbation rates; may not distinguish anxiety from asthma',
         'Psychological support; distinguish from VCD; optimise asthma control'],
        ['Vocal cord dysfunction (ILO)',
         'Can mimic OR coexist with asthma; inspiratory stridor; commoner in women',
         'Laryngoscopy during symptoms; speech therapy; treat anxiety; NOT responsive to bronchodilators'],
    ]
    story.append(make_table(comor_headers, comor_rows,
                            [4.0*cm, 5.5*cm, W-9.5*cm], header_bg=ORANGE))

    story.append(PageBreak())

    # ══════════════════════════════════════════════════════════════════
    # PAGE 6 – DRUG MECHANISMS & QUICK REFERENCE
    # ══════════════════════════════════════════════════════════════════
    story.append(SP(0.2))
    story.append(section_header('6.  DRUG MECHANISMS & QUICK REFERENCE', MED_BLUE))
    story.append(SP(0.3))

    # Drug mechanism table
    story.append(p('MECHANISM OF ACTION – KEY DRUG CLASSES', H2))
    story.append(HR(MED_BLUE, 1.5, 2, 5))

    drug_headers = ['Drug Class', 'Mechanism', 'Key Points']
    drug_rows = [
        [p('<b>SABA\n</b>Salbutamol,\nLevalbuterol', TC_B),
         'β₂ receptor → Gs → ↑cAMP → PKA → MLCK inhibition\n+ opens K⁺ channels → hyperpolarisation → SM relaxation',
         '⚠ NEVER use as monotherapy (increased mortality). '
         'Onset 3–5 min. Duration 4–6h. Side effects: tremor, tachycardia, hypokalaemia, Type B lactic acidosis.'],
        [p('<b>LABA\n</b>Formoterol (rapid)\nSalmeterol (slow)', TC_B),
         'Same as SABA. Formoterol = moderate lipophilicity (rapid + sustained).\nSalmeterol = anchored in exosite (slow onset)',
         'Duration ~12h. FORMOTEROL can be reliever (rapid onset). SALMETEROL cannot. '
         'NEVER use as monotherapy in asthma.'],
        [p('<b>ICS\n</b>Budesonide,\nFluticasone,\nCiclesonide', TC_B),
         'Binds GR → nuclear translocation → trans-repression of NF-κB/AP-1\n→ ↓IL-4, IL-5, IL-13, TNF-α, iNOS',
         'Oral bioavailability: Beclomethasone 20%; Budesonide 10–15%; Fluticasone ~1%; Mometasone <1%; '
         'Ciclesonide = pro-drug (activated in lung). Reduces FeNO + eosinophils + AHR. '
         'Side effects: growth suppression (children), osteoporosis, cataracts.'],
        [p('<b>LAMA\n</b>Tiotropium,\nUmeclidinium', TC_B),
         'M₃ receptor blockade → ↓ACh-induced smooth muscle contraction;\nfunctional selectivity M₃/M₁ > M₂',
         'Add-on Step 4–5. Note: blocking M₂ (autoinhibitory) would → ↑ACh release – '
         'LAMAs have favourable kinetics avoiding this. Side effects: dry mouth, urinary retention, glaucoma (high dose).'],
        [p('<b>LTRA\n</b>Montelukast,\nZafirlukast', TC_B),
         'CysLT₁ receptor antagonism → blocks LTC₄/LTD₄/LTE₄\n→ ↓bronchoconstriction, ↓mucus, ↓eosinophil recruitment',
         '⚠ FDA BLACK BOX: Montelukast → serious neuropsychiatric effects (suicidal ideation, depression). '
         'Alternative Step 2. Good for AERD and EIB. Reduces BOTH early and late phase response.'],
        [p('<b>IV Mg²⁺\n</b>Sulphate', TC_B),
         'Competes with Ca²⁺ → inhibits smooth muscle contraction;\nantagonises Ca²⁺-dependent mediator release from mast cells',
         '2g IV over 20 min. Single dose. For severe/life-threatening acute asthma. '
         'Reduces hospitalisation rate and intubation need. Safe; mild hypotension risk.'],
        [p('<b>Theophylline', TC_B),
         'Inhibits phosphodiesterase → ↑cAMP + ↑cGMP\nAlso: adenosine receptor antagonism; restores HDAC2 activity (low dose)',
         'Now RARELY used for asthma. Narrow therapeutic window. '
         'Interactions: erythromycin, ciprofloxacin, rifampicin. '
         'Low-dose theophylline may partially reverse steroid resistance via HDAC2.'],
    ]
    story.append(make_table(drug_headers, drug_rows,
                            [2.8*cm, 5.0*cm, W-7.8*cm]))
    story.append(SP(0.4))

    # ICS potency/bioavailability comparison
    story.append(p('ICS COMPARISON – ORAL BIOAVAILABILITY & PROPERTIES', H2))
    story.append(HR(MED_BLUE, 1.5, 2, 5))

    ics_headers = ['ICS Agent', 'Oral Bioavail.', 'Half-life', 'Special Feature', 'Pregnancy']
    ics_rows = [
        ['Beclomethasone dipropionate', '~20%', '0.5h (BDP) → 17-BMP active', 'Oldest; oropharyngeal deposition issue; pMDI fine particle', 'B'],
        ['Budesonide', '~10–15%', '2–3h', 'Both pMDI and DPI; reference standard ICS', '★ Safe'],
        ['Fluticasone propionate', '~1%', '14h', 'High topical potency; commonly combined with salmeterol/vilanterol', 'B'],
        ['Fluticasone furoate', 'Negligible', '24h', 'Once-daily; only with vilanterol (ultra-LABA)', 'B'],
        ['Mometasone furoate', '<1%', '5h', 'Very low oral BA; combined with formoterol/indacaterol', 'C'],
        ['Ciclesonide', '<1%', '0.7h (parent) 45h (active)', 'Pro-drug activated in lung by esterases; NO oropharyngeal deposition', 'C'],
    ]
    story.append(make_table(ics_headers, ics_rows,
                            [3.8*cm, 2.5*cm, 3.2*cm, 5.0*cm, 1.8*cm]))
    story.append(SP(0.3))

    # Quick reference summary box
    story.append(info_box(
        '📋  QUICK CLINICAL REFERENCE SUMMARY',
        [
            p('<b>T2 biomarkers positive (FeNO ≥40, eos ≥300, IgE elevated) + severe:</b> Step up to biologic. '
              'Choose based on dominant comorbidity (atopic → omalizumab/dupilumab; eosinophilic → anti-IL-5; '
              'no biomarker dominance → tezepelumab).', BODY),
            p('<b>Normal PaCO₂ in a distressed asthmatic = DANGER:</b> Impending respiratory failure. '
              'Do not be falsely reassured. Prepare for intubation.', WARN),
            p('<b>ICS/formoterol (AIR) is now preferred at ALL steps</b> per GINA 2026 – not just steps 3–4.', BODY),
            p('<b>Before stepping up:</b> Always check adherence (responsible for ≥50% of "refractory" cases), '
              'inhaler technique, triggers, and comorbidities first.', BODY),
            p('<b>Permissive hypercapnia</b> during MV in status asthmaticus: accept PaCO₂ rising; '
              'target pH ≥7.2; use NaHCO₃ if pH <7.2; ketamine for induction.', BODY),
            p('<b>Montelukast:</b> FDA black box warning for neuropsychiatric effects – inform patients before prescribing.', WARN),
            p('<b>Depemokimab (GINA 2026):</b> Newest anti-IL-5 biologic; SC every 6 months; '
              'longest dosing interval of any approved biologic for asthma.', BODY),
        ], LIGHT_BLUE, MED_BLUE))
    story.append(SP(0.4))

    # Sources
    story.append(HR(GREY_MED, 0.5, 4, 4))
    story.append(p('<b>Sources:</b> GINA Global Strategy for Asthma Management and Prevention 2026 (released May 5, 2026); '
                   'Harrison\'s Principles of Internal Medicine 22E (2025), Chapter 298; '
                   'Goodman & Gilman\'s Pharmacological Basis of Therapeutics, Chapter 44; '
                   'Fishman\'s Pulmonary Diseases and Disorders; '
                   'Murray & Nadel\'s Textbook of Respiratory Medicine; '
                   'Systematic Reviews: PMID 40520782 (biologics umbrella review, 2025).', NOTE))
    story.append(p('Prepared for Respiratory Medicine PGT educational use. '
                   'Not a substitute for clinical judgment. All treatment decisions should be guided by '
                   'local guidelines, specialist review, and individual patient assessment.', NOTE))

    return story


# ─────────────────────────── MAIN ─────────────────────────────────────
def main():
    doc = make_doc()
    story = build_story()

    # Build with page templates
    doc.build(
        story,
        onFirstPage=build_cover,
        onLaterPages=build_page_header_footer,
    )
    print(f'✅  PDF created: {OUTPUT}')

if __name__ == '__main__':
    main()

Running Command

cd /home/daytona/workspace/asthma-pdf && python3 generate_asthma_pdf.py 2>&1

Editing File

~/asthma-pdf/generate_asthma_pdf.py

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/asthma-pdf/generate_asthma_pdf.py'

Running Command

cd /home/daytona/workspace/asthma-pdf && python3 generate_asthma_pdf.py 2>&1

Editing File

~/asthma-pdf/generate_asthma_pdf.py

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/asthma-pdf/generate_asthma_pdf.py'

Running Command

cd /home/daytona/workspace/asthma-pdf && python3 generate_asthma_pdf.py 2>&1

Running Command

ls -lh /home/daytona/workspace/asthma-pdf/Asthma_Management_Reference.pdf

Your reference PDF is ready:

Asthma Management Reference
PDF Document · PDF

What's inside (6 pages, colour-coded)

Page	Content
Cover	Title page with 4 topic tiles (GINA 2026, Biologics, Acute Asthma, Biomarkers)
Page 1	Definition, epidemiology key facts, diagnostic criteria table, biomarker interpretation table (FeNO / Blood Eos / IgE / Sputum Eos / Periostin)
Page 2	GINA 2026 5-step algorithm (colour-coded Steps 1–5), AIR paradigm box, stepping up/down rules, OCS minimisation guidance
Page 3	T2 inflammatory cascade diagram, all 8 biologics comparison table (targets, routes, thresholds, notes), biologic selection algorithm by phenotype
Page 4	ABG evolution in acute asthma (colour-coded stages), severity grading table, GINA 2026 acute management protocol, ATS/IDSA severe CAP criteria
Pages 5–6	GINA 2026 fatality risk indicators, special scenarios (AERD, ACO, pregnancy, EIB) in 2-column layout, comorbidities table, drug mechanism table, ICS comparison table, quick clinical reference summary box

Colour scheme: Green = mild/safe, Blue = information, Orange = caution, Red = danger/severe, Purple = biologics, Teal = GINA steps.

Tell me about copd in detail for final exam

Finding Sources

Searching PubMed

"COPD" AND "GOLD guidelines" AND "management"

Searching the Web

GOLD 2025 2026 COPD guidelines update management classification

Reading File

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC13109179

Finding Sources

Reading File

Finding Sources

Searching PubMed

"COPD" AND "exacerbation" AND "treatment"

Loading Image

Finding Sources

I now have comprehensive material from textbooks + GOLD 2026. Here is the full detailed answer:

COPD - Comprehensive Final Exam Guide

Based on GOLD 2026 | Harrison's 22E | Fishman's Pulmonary | Robbins Pathology | Katzung Pharmacology

1. DEFINITION

COPD is a heterogeneous lung condition characterised by chronic respiratory symptoms (dyspnoea, cough, sputum production, exacerbations) due to abnormalities in the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction that is NOT fully reversible.

GOLD 2026 Conceptual Update: COPD is now framed as a disease of ongoing activity - defined by airway inflammation, symptom variability, and exacerbation risk - rather than just a static measure of airflow limitation.

Key diagnostic criterion: Post-bronchodilator FEV₁/FVC < 0.70 on spirometry.

2. EPIDEMIOLOGY

Parameter	Value
Global prevalence	~391 million people; ~10% of adults
Global mortality	3rd leading cause of death worldwide
US deaths	~150,000/year
Economic cost	>$40 billion/year in the US alone
Smoker risk	Previously cited as 15-30% of smokers; now higher with CT data showing subclinical disease in many more

COPD is underdiagnosed and undertreated - a major theme of GOLD 2026. The 2025 World COPD Day theme was "Think COPD."

3. ETIOLOGY & RISK FACTORS

Major Risk Factors

Cigarette smoking (by far the most important): dose-dependent; pack-years correlate with severity
Biomass fuel exposure (cooking smoke - major cause in low-income countries, especially women)
Occupational exposures: coal dust, silica, grain dust, cadmium
Air pollution (indoor + outdoor)
Recurrent respiratory infections in childhood
Low birth weight / impaired lung development
Alpha-1 antitrypsin (A1AT) deficiency - genetic cause

Alpha-1 Antitrypsin Deficiency (Important Exam Topic)

Autosomal co-dominant inheritance
PiZZ phenotype = severe deficiency; PiMZ = intermediate
A1AT is a serine protease inhibitor that neutralises neutrophil elastase
Deficiency → unopposed elastase activity → panacinar emphysema (lower lobe predominant)
Also causes liver cirrhosis (misfolded protein accumulates in hepatocytes)
ATS recommends testing all patients with persistent airflow obstruction for A1AT levels
Treatment: intravenous A1AT augmentation therapy (weekly IV infusions)

4. PATHOLOGY

4a. Emphysema Types

(From Rosen's Emergency Medicine - showing panacinar (A) with uniform acinar enlargement vs. centriacinar (B) with proximal respiratory bronchiole inflammation)

Type	Anatomy	Cause	Distribution
Centriacinar (Centrilobular)	Enlargement of proximal respiratory bronchioles (RB1-3); alveolar sacs preserved	Cigarette smoking	Upper lobe predominant
Panacinar (Panlobular)	Uniform destruction of entire acinus from TB to alveolar sacs	A1AT deficiency	Lower lobe predominant
Paraseptal	Distal acinus; subpleural; near septa	Often idiopathic	Upper lobe; causes spontaneous pneumothorax
Irregular (Scar)	Around areas of fibrosis/scarring	Post-inflammatory	Adjacent to scars

4b. Chronic Bronchitis Pathology

Clinical definition: Productive cough for ≥3 months in ≥2 consecutive years (no other cause)
Pathological changes:
- Reid index >0.4 (gland thickness / bronchial wall thickness; normal <0.4)
- Hyperplasia of submucosal mucous glands (Reid index)
- Goblet cell metaplasia in small airways
- Inflammatory infiltrate (predominantly neutrophilic)
- Bronchiolar wall fibrosis
- Ciliary dysfunction → impaired mucociliary clearance
MUC5AC concentration increased 10-fold, MUC5B 3-fold in severe COPD (Fishman's)

5. PATHOPHYSIOLOGY

5a. Protease-Antiprotease Imbalance

This is the central mechanism of emphysema:

Trigger: Cigarette smoke / noxious particles → oxidative stress → recruit neutrophils and macrophages
Neutrophils release elastase (matrix metalloproteinases + serine proteases)
A1AT (produced by liver) normally inhibits neutrophil elastase
Oxidative stress from cigarette smoke inactivates A1AT
Net result: Unopposed elastase destroys elastin and type IV collagen in alveolar walls → enlarged airspaces → emphysema
Loss of elastic recoil → airway collapse on expiration → airflow obstruction

5b. Inflammation Profile

Dominant cell: Neutrophil (unlike asthma which is eosinophilic)
Also: CD8+ T-cells, macrophages, mast cells in some patients
Inflammatory mediators: IL-8, TNF-α, LTB₄, MMP-9, MMP-12
ICS are poorly effective because neutrophilic inflammation is corticosteroid-resistant

5c. Small Airway Disease

Earliest change: Inflammation and fibrosis of small airways (<2mm diameter)
Small airways account for only 25% of total airway resistance normally, but become major site of obstruction in COPD
Small airway obstruction precedes detectable spirometric changes
CT can detect small airway mucus plugging even with preserved FEV₁

5d. Dynamic Hyperinflation (Important Exam Mechanism)

From Fishman's Pulmonary:

Loss of elastic recoil → static hyperinflation (increased FRC at rest)
During exercise: increased ventilatory demand + insufficient expiratory time → air trapping → dynamic hyperinflation
End-expiratory lung volume (EELV) rises → inspiratory reserve volume (IRV) falls critically
Creates neuromechanical uncoupling (effort disproportionate to VT response) → sensation of dyspnoea
Barrel chest = compensatory increase in AP diameter due to chronically elevated FRC
Flattened diaphragm on CXR/CT due to hyperinflation

5e. Gas Exchange Abnormalities

From Costanzo Physiology clinical case:

V/Q mismatch is the primary mechanism of hypoxaemia in COPD
Perfused but poorly ventilated alveoli (low V/Q) → venous admixture → ↓PaO₂
Unlike asthma, A-a gradient is elevated (measured PaO₂ << calculated PAO₂)
Alveolar gas equation: PAO₂ = PiO₂ - PaCO₂/R = 150 - PaCO₂/0.8
Early COPD: Hypoxaemia + hypocapnia (hyperventilation compensates)
Late COPD (type B "blue bloater"): Hypoxaemia + hypercapnia + respiratory acidosis
Emphysema patients tend to maintain normocarbia longer ("pink puffer")

5f. Pink Puffer vs Blue Bloater (Classic Teaching)

Feature	Pink Puffer (Emphysema type)	Blue Bloater (Bronchitic type)
Dominant pathology	Emphysema	Chronic bronchitis
Body habitus	Thin, cachexic	Overweight
Cyanosis	Absent (pink)	Present (blue)
SpO₂	Relatively preserved	Low
PaCO₂	Normal/low (hyperventilates)	Elevated (hypercapnic)
Cor pulmonale	Late	Earlier
Pursed-lip breathing	Yes	No
Note: In clinical reality, most patients are mixed

6. CLINICAL FEATURES

Symptoms (Classic Triad)

Dyspnoea - progressive, worse on exertion; described as "breathlessness" or "air hunger"; MRC scale used
Chronic cough - may be intermittent; productive or dry
Sputum production - chronic bronchitis phenotype; purulent during exacerbations

Signs

Sign	Mechanism
Barrel chest (↑ AP diameter)	Static hyperinflation
Pursed-lip breathing	Self-PEEP to prevent dynamic airway collapse
Accessory muscle use (SCM, scalenes)	Increased WOB; hyperinflation flattens diaphragm
Hoover sign	Paradoxical inward movement of lower ribs on inspiration
Reduced breath sounds	Airway obstruction + hyperinflation
Wheeze	Airway narrowing
Prolonged expiratory phase	Increased airway resistance
Cyanosis	Hypoxaemia (type B phenotype)
Ankle oedema + JVP elevation	Cor pulmonale (right heart failure)
Tripod positioning	Fixes shoulder girdle to use accessory muscles

7. INVESTIGATIONS

Spirometry (Mandatory for Diagnosis)

GOLD Grade	Post-BD FEV₁/FVC	FEV₁ (% predicted)
Diagnosis	< 0.70	Any
GOLD 1 (Mild)	< 0.70	≥ 80%
GOLD 2 (Moderate)	< 0.70	50–79%
GOLD 3 (Severe)	< 0.70	30–49%
GOLD 4 (Very Severe)	< 0.70	< 30%

Note: Fixed ratio (FEV₁/FVC <0.70) may over-diagnose in the elderly. Some guidelines prefer LLN (lower limit of normal), but GOLD 2026 retains the 0.70 threshold.

Chest X-Ray (CXR) Findings

Hyperinflation: >6 anterior ribs visible; flat hemidiaphragms (below rib 6 anteriorly)
Increased AP diameter on lateral view
Hyperlucent lung fields (reduced vascular markings)
Bullae formation
Increased retrosternal airspace on lateral CXR

HRCT Thorax

Low-attenuation areas = emphysema (quantified as % of lung below -950 HU threshold)
Air trapping on expiratory CT
Small airway mucus plugging
Airway wall thickening (chronic bronchitis)
Bronchiectasis (15-30% of COPD patients have concomitant bronchiectasis)

Blood Tests

FBC: Polycythaemia (chronic hypoxia → ↑EPO → ↑RBC)
ABG: Hypoxaemia ± hypercapnia; pH; HCO₃⁻ (chronic compensation)
A1AT level: Test all patients with airflow obstruction (ATS recommendation)
Blood eosinophil count (BEC): Critical biomarker for treatment decisions (ICS, dupilumab)
BNP/NT-proBNP: Elevated in cor pulmonale / right heart failure

ECG

P pulmonale (peaked P waves >2.5mm in II, III, aVF)
Right axis deviation
Right ventricular hypertrophy pattern
Low voltage (hyperinflation)

8. GOLD ABE CLASSIFICATION (GOLD 2026 Update)

GOLD 2026 has consolidated the transition from ABCD → ABE framework.

Assessment Dimensions

Spirometry (GOLD grade 1-4) - for severity of airflow obstruction
Symptoms - assessed with mMRC ≥2 or CAT ≥10
Exacerbation history - key determinant of treatment

Groups A, B, E

Group	Exacerbation History	Symptoms	Initial Therapy
A	0 exacerbations in past year	mMRC 0–1 / CAT <10	Short- or long-acting bronchodilator (LAMA preferred if available)
B	0 exacerbations in past year	mMRC ≥2 / CAT ≥10	LABA + LAMA (dual bronchodilation)
E ("Exacerbator")	≥1 moderate exacerbation (NEW GOLD 2026) or ≥2 moderate or ≥1 severe	Any symptom level	LABA + LAMA ± ICS (based on blood eosinophils)

GOLD 2026 Key Change: Group E threshold lowered - now includes patients with even a single moderate exacerbation in the prior year (previously required ≥2 moderate or ≥1 hospitalisation).

Rationale: A single moderate exacerbation is associated with accelerated FEV₁ decline, increased risk of future exacerbations, and higher mortality.

9. PHARMACOLOGICAL MANAGEMENT

9a. Bronchodilators (Mainstay)

LAMAs (Long-Acting Muscarinic Antagonists):

Tiotropium (Spiriva), umeclidinium, glycopyrronium, aclidinium
Mechanism: M₃ receptor blockade → ↓ACh-mediated bronchoconstriction; also reduce mucus secretion
Once daily (tiotropium, umeclidinium) or twice daily
Preferred initial bronchodilator in COPD (outperform LABAs on lung function + exacerbations in most head-to-head trials)

LABAs (Long-Acting Beta-2 Agonists):

Salmeterol, formoterol, indacaterol, olodaterol, vilanterol
Duration 12h (salmeterol, formoterol) or 24h (indacaterol, vilanterol, olodaterol)

Dual Bronchodilation (LABA + LAMA):

Preferred for Group B and most Group E patients
Greater bronchodilation + exacerbation reduction vs. monotherapy
Examples: umeclidinium/vilanterol (Anoro), tiotropium/olodaterol (Spiolto), glycopyrronium/indacaterol (Ultibro)

SABAs and SAMAs:

Salbutamol (SABA), ipratropium (SAMA)
For rescue/PRN use
Combined SABA+SAMA (combivent) for acute use

9b. Inhaled Corticosteroids (ICS) - Conditional Use

Unlike asthma, ICS are NOT first-line in COPD.

Blood Eosinophil Count	ICS Recommendation
≥300 cells/µL	ICS likely beneficial; add to LABA/LAMA
100–299 cells/µL	Consider ICS; weigh benefits vs risks
<100 cells/µL	ICS unlikely to benefit; associated with ↑ pneumonia risk

Indications for ICS in COPD:

Persistent exacerbations despite LABA+LAMA
BEC ≥300 cells/µL
Concurrent asthma-COPD overlap (ACO) - ICS mandatory

ICS risks in COPD:

Pneumonia (most important - relative risk ↑ with FP vs budesonide)
Oral candidiasis
HPA axis suppression
Osteoporosis

9c. Triple Therapy (LABA + LAMA + ICS)

For Group E patients with persistent exacerbations despite LABA+LAMA
Particularly when BEC ≥100 (more benefit with higher eosinophils)
GOLD 2026: Triple therapy threshold lowered; more prominently integrated
Evidence: IMPACT, ETHOS, TRINITY, TRIBUTE trials - all show class effect in reducing exacerbations and improving FEV₁

Single-inhaler triple therapy examples:

Budesonide/formoterol/glycopyrronium (Breztri Aerosphere)
Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta)

9d. Roflumilast (PDE4 Inhibitor)

Selective phosphodiesterase-4 inhibitor → ↑cAMP → anti-inflammatory
Indication: GOLD 3-4 + chronic bronchitis phenotype + frequent exacerbations despite maximal ICS/LABA/LAMA
Reduces exacerbations by ~15-17%
Side effects: Nausea, diarrhoea, weight loss, psychiatric effects - limit use
Note: Not a bronchodilator - purely anti-inflammatory

9e. Azithromycin (Long-term antibiotic)

250mg/day or 500mg 3×/week
Reduces exacerbation frequency by ~27% in selected patients
Mechanism: Anti-inflammatory + anti-bacterial (against H. influenzae, non-typeable H. influenzae)
Concerns: Hearing loss, cardiac arrhythmias (QTc prolongation), antibiotic resistance
Indication: Former/non-smokers, frequent exacerbators, elderly

9f. Mucolytics

N-acetylcysteine (NAC), carbocisteine, erdosteine
Reduce viscosity of mucus; some antioxidant effect
Recent systematic review (PMID: 39413571, 2024): modest benefit on exacerbation reduction in stable COPD
Indicated especially in chronic bronchitis phenotype

9g. Biologics (GOLD 2026 - New Integration)

This is a major GOLD 2026 update:

Dupilumab (anti-IL-4Rα):

BOREAS and NOTUS trials
Indication: COPD + chronic bronchitis phenotype + BEC ≥300 cells/µL + uncontrolled on triple therapy
Reduces moderate-severe exacerbations by 30-34% + improves FEV₁
Only biologic currently with strong evidence base for COPD
GOLD 2026 positions this as an additional option after triple therapy failure in eosinophilic COPD

Mepolizumab (anti-IL-5):

PMID: 40626315 (2025 network meta-analysis) supports type-2 biologics in COPD
Evidence emerging but not yet as strong as dupilumab

10. NON-PHARMACOLOGICAL MANAGEMENT

Smoking Cessation

Single most effective intervention to slow FEV₁ decline
Fletcher-Peto curves: accelerated FEV₁ decline in susceptible smokers; stops with cessation
Methods: Nicotine replacement therapy (NRT), varenicline (preferred: 2× more effective), bupropion, behavioural support
Even after decades of smoking - cessation slows progression

Pulmonary Rehabilitation (PR)

Strongest evidence for improving dyspnoea, exercise capacity, and QoL
Does NOT improve FEV₁ or mortality significantly in isolation
Components: Aerobic exercise, strength training, education, nutritional support, psychosocial support
Duration: 6-8 weeks (minimum); 12 weeks preferred
Must be initiated within 4 weeks after exacerbation (post-exacerbation PR reduces readmissions)

Long-Term Oxygen Therapy (LTOT)

Indications (NICE/ATS - requires 2 measurements ≥3 weeks apart):

PaO₂ ≤55 mmHg (7.3 kPa) at rest on room air
PaO₂ 56-59 mmHg (7.3-8.0 kPa) PLUS one of: cor pulmonale, polycythaemia (Hct >55%), pulmonary hypertension

Prescription: ≥15 hours/day (including sleep); SpO₂ target 88-92% in COPD (avoid hyperoxia)

Benefits: Reduces mortality by ~30%; reduces pulmonary hypertension progression; reduces polycythaemia; improves exercise tolerance

Evidence: NOTT trial (1980) and MRC trial established LTOT benefit.

Vaccination (GOLD 2026 - Core Disease-Modifying Strategy)

Vaccine	Recommendation
Influenza	Annual; all COPD patients
Pneumococcal (PCV13/PCV20 + PPSV23)	All COPD patients
COVID-19	All COPD patients
RSV (RSVpreF / RSVmAb)	≥60 years with COPD
Tdap/Td	If not previously vaccinated

Lung Volume Reduction Surgery (LVRS)

Removes most diseased portions of lung (typically upper lobes)
Improves elastic recoil, reduces hyperinflation, improves diaphragm mechanics
Best candidates: Upper-lobe predominant emphysema + low exercise capacity after PR
NETT trial: Mortality benefit in upper-lobe COPD with low post-PR exercise

Bronchoscopic Lung Volume Reduction (BLVR)

Endobronchial valves (Zephyr, Spiration): one-way valves → lobar atelectasis → reduce hyperinflation
Coils, thermal vapour ablation - alternative modalities
Requires absence of collateral ventilation (Chartis assessment or fissure completeness on CT)

Lung Transplantation

End-stage COPD (GOLD 4) failing maximal therapy
Single or bilateral lung transplant
BODE index used for listing prioritisation (BMI, Obstruction, Dyspnoea, Exercise)

11. EXACERBATIONS OF COPD (AECOPD)

Definition

Acute worsening of respiratory symptoms beyond day-to-day variation requiring a change in therapy.

Triggers

Viral infections: 50-80% (rhinovirus, influenza, parainfluenza, RSV, coronavirus)
Bacterial infections: 40-60% H. influenzae (most common), Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas (severe COPD)
Air pollution
Pulmonary embolism (frequently overlooked - check D-dimer/CTPA)

Severity Classification (GOLD 2026 Revised)

Severity	Definition	Setting
Mild	Managed by patient alone; increased SABA only	Home
Moderate	Requires medical intervention; antibiotics ± steroids	Outpatient
Severe	Requires hospitalisation; life-threatening	Inpatient / ICU

Management of Acute Exacerbation

Bronchodilators:

Increase dose/frequency of SABAs (salbutamol 2.5-5mg neb q20min)
Add ipratropium 0.5mg neb
Continue LABAs and LAMAs

Systemic Corticosteroids:

Prednisolone 30-40mg/day for 5 days (REDUCE trial: 5 days = 14 days; no benefit to longer)
Reduces exacerbation duration and hospital stay

Antibiotics:

Indicated if: purulent sputum AND increased dyspnoea AND increased sputum volume (Anthonisen criteria - 2 or 3 = antibiotics)
Or if mechanically ventilated
Choice: Amoxicillin/clavulanate, doxycycline, or azithromycin
Pseudomonas coverage if: severe COPD (FEV₁ <30%), hospitalised, prior Pseudomonas infection, immunocompromised → ciprofloxacin or anti-pseudomonal beta-lactam

Oxygen:

Target SpO₂ 88-92% (controlled oxygen; avoid hyperoxia)
High-flow O₂ → ↑ PaCO₂ (Haldane effect + absorption atelectasis + ↓hypoxic drive) → hypercapnic respiratory failure

Non-Invasive Ventilation (NIV/BiPAP):

Indication: pH <7.35 + PaCO₂ >45 mmHg (type 2 respiratory failure)
Reduces need for intubation by ~58%, reduces mortality ~48%
IPAP 12-20 cmH₂O, EPAP 4-8 cmH₂O, FiO₂ titrated
Contraindications: Vomiting, unable to protect airway, facial trauma, haemodynamic instability

High-Flow Nasal Oxygen (HFNC):

GOLD 2026 now includes HFNC as a modality in exacerbation management
Better tolerated than NIV; useful in milder type 2 failure or NIV intolerance

Intubation/MV:

Failure of NIV, pH <7.25, haemodynamic instability
Strategy: Low RR + longer expiratory time (I:E 1:3) to avoid auto-PEEP; permissive hypercapnia

12. COMPLICATIONS

Complication	Mechanism
Cor pulmonale	Chronic hypoxia → hypoxic vasoconstriction → pulmonary hypertension → RV hypertrophy/failure
Polycythaemia	Chronic hypoxia → ↑EPO → ↑RBC mass
Spontaneous pneumothorax	Rupture of paraseptal bullae (especially young male with upper-lobe paraseptal emphysema)
Respiratory failure (Type 1 and 2)	Progressive V/Q mismatch; later hypoventilation
Pulmonary hypertension	Leads to CXR: prominent hila, right heart enlargement
Malnutrition/cachexia	Increased WOB + systemic inflammation (TNF-α)
Muscle wasting	Systemic inflammation + deconditioning
Depression/anxiety	~40% prevalence; worsens outcomes
Lung cancer	5-6× increased risk; smoking + inflammation + air trapping
Atrial fibrillation	Common comorbidity; hypoxia, catecholamines, RV strain

13. PROGNOSTIC INDICES

BODE Index (Best validated prognostic tool)

Variable	Score 0	Score 1	Score 2	Score 3
BMI	>21	≤21	-	-
Obstruction (FEV₁%)	≥65%	50-64%	36-49%	≤35%
Dyspnoea (mMRC)	0-1	2	3	4
Exercise (6MWT, m)	≥350	250-349	150-249	≤149

BODE score: 0-10; higher = worse prognosis. Used for lung transplant listing.

Other Predictors

Exacerbation frequency (each exacerbation accelerates FEV₁ decline)
6-minute walk distance (6MWT) - most prognostically powerful single test
FEV₁ decline rate (>50 mL/year = accelerated)
CT emphysema quantification

14. ASTHMA-COPD OVERLAP (ACO)

Features of both asthma and COPD: variable obstruction + incomplete reversibility
Spirometry: Post-BD FEV₁/FVC <0.70 + some reversibility (FEV₁ ↑ ≥12% AND ≥200 mL)
Often: atopic history, blood eosinophilia, elevated FeNO, smoking history
Critical rule: ICS is MANDATORY in ACO (unlike pure COPD where it is conditional)
LABA + LAMA can both be used
⚠ LABA monotherapy (without ICS) is contraindicated in ACO

15. KEY HIGH-YIELD EXAM POINTS

Topic	High-Yield Fact
Diagnostic criterion	Post-BD FEV₁/FVC <0.70 (GOLD); not reversible to normal
Most common cause	Cigarette smoking
Genetic cause	A1AT deficiency → panacinar emphysema, lower lobes
Centriacinar emphysema	Smoking; upper lobes; most common type
Reid index	>0.4 in chronic bronchitis (gland/wall thickness)
Pink puffer vs blue bloater	Emphysema vs bronchitis phenotype
ABG in COPD exacerbation	pH ↓, PaCO₂ ↑, PaO₂ ↓ (type 2 RF)
O₂ target in COPD	88-92% SpO₂ (NOT 95-98% - risk of hypercapnia)
Hypercapnia mechanism	V/Q mismatch + Haldane effect with high-flow O₂
ICS in COPD	Only if BEC ≥300 OR persistent exacerbations; NOT first-line
ICS risk unique to COPD	Increased pneumonia risk
LABA monotherapy	CONTRAINDICATED in asthma; acceptable in COPD
GOLD 2026 Group E threshold	Lowered - now includes single moderate exacerbation
Triple therapy trials	IMPACT, ETHOS, TRINITY, TRIBUTE
LTOT indication	PaO₂ ≤55 mmHg OR 56-59 with cor pulmonale/polycythaemia
LTOT duration	≥15 hours/day
Steroid course in exacerbation	5 days prednisolone 30-40mg (REDUCE trial)
NIV indication	pH <7.35 + PaCO₂ >45 (type 2 RF)
Smoking cessation drug	Varenicline > NRT > bupropion
Most effective single intervention	Smoking cessation (slows FEV₁ decline)
New GOLD 2026 biologic	Dupilumab - for COPD + chronic bronchitis + BEC ≥300 on triple therapy
BODE score	BMI + Obstruction + Dyspnoea + Exercise; 0-10
Roflumilast indication	GOLD 3-4 + chronic bronchitis + frequent exacerbators on maximal therapy

Sources: GOLD 2026 Global Strategy (goldcopd.org); PMC13109179 (GOLD 2026 review); Katzung's Pharmacology 16E Ch.44; Fishman's Pulmonary Diseases; Robbins Basic Pathology; Rosen's Emergency Medicine; Costanzo Physiology 7E; Murray & Nadel's Respiratory Medicine; PMID 40626315 (biologics NMA in COPD, 2025).

Tell me about interstitial lung disease

Reading File

Finding Sources

Searching the Web

ILD interstitial lung disease 2025 2026 guidelines ATS ERS classification treatment update

Searching PubMed

"interstitial lung disease" AND "diagnosis" AND "treatment"

Reading File

Finding Sources

Reading File

Finding Sources

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Generate a comprehensive ILD reference PDF with classifications, diagnostics, and treatment algorithms

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Tell me all about lakshya from gynae and obs.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.